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Dopamine receptors mediate various important neurophysiological functions1. At a 
molecular level, G protein coupling is considered the main activation mechanism for most of the 
receptor-mediated cellular processes1. A number of studies using native tissue have supported the 
idea that receptors can interact to form dimers or higher order oligomers3, 4. Particularly in 
medium spiny neurons of the striatum, dopamine receptor subtypes are reported to form dimers 
with themselves5-7 or other receptors (e.g. adenosine receptor A2A8). Although a functional 
relevance for these dimers has been proposed, current assay systems are not capable of teasing 
out dimer-specific signaling events from those from other receptor populations. We have 
developed an assay that allows investigation of receptor-effector coupling specifically with defined 
dimer pairs. Using this assay, we investigated putative dopamine D1-D2 and A2A-D2 receptor 
dimer functions and studied the issue of a purported G protein coupling switch in the D1-D2 
receptor dimer in which the heteromer was proposed to activate Gq, unlike D1 or D2 receptor 
when expressed alone9. We were unable, however, to find evidence for Gq activation by the D1-
D2 heteromer, as the protomers in the heteromer maintained fidelity of signaling to their cognate 
G proteins. We also developed and optimized a series of novel Gs biosensors to elucidate 
 
 
differences in heterotrimeric G protein conformational changes triggered by dopamine D1 and 
A2A receptors, two of the prominent pharmacological targets in the striatum. 
In addition to G protein signaling, intracellular calcium is also involved in many important 
cellular functions in all cell types. In neurons, intracellular calcium is implicated in learning and 
memory (synaptic plasticity10) as well as neurodegeneration (apoptosis11). In medium spiny 
neurons, dopamine-mediated calcium release from internal stores has been reported to result 
from activation of phospholipase C (PLC). However, different subtypes of dopamine receptors and 
intermediary proteins have been proposed to play a role in this dopamine-mediated PLC 
activation, and the underlying mechanisms are unclear. We found that activation of D1 and D2 
receptors expressed individually can mobilize calcium in a PLC-dependent manner.  In parallel, we 
also examined D1 and D2 receptor colocalization in striatal brain slices as well as in cultured 
medium spiny neurons. Although we found evidence using bacterial artificial chromosome-D1 and 
D2 reporter mice that D1 and D2 receptors are co-expressed in a small number of brain regions, 
we failed to observe D1-D2 receptor colocalization, suggesting the possibility that in neurons the 
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Chapter 1 : Introduction 
 
Dopamine circuitry, physiology, and its dysfunction in the brain 
Dopamine (DA) neurotransmission regulates many of the crucial neurological and 
psychiatric functions that result in cognition, motivation, voluntary movement, and reward. 
Abnormal DA neurotransmission causes dysfunction in these functions and is identified as a major 
contributor to the pathophysiology of illnesses including schizophrenia, attention deficit 
hyperactivity disorder, Parkinson’s disease, and drug addiction. Therefore, modification of 
abnormal DA neurotransmission and signaling has been pursued as a therapeutic target and is a 
very active area of research. My thesis project is intended to better understand DA 
neurotransmission at the level of the receptor by elucidating the molecular functions of DA 
receptor-receptor complexes. 
As with other monoaminergic transmitters, DA employs slow metabotropic modulation on 
connected neurons by mediating glutamate and GABA neurotransmission. DAergic innervations 
form intricate circuitry in the brain with four major DAergic pathways (Figure 1-1a); the 
nigrostriatal, mesolimbic, mesocortical (often called together the mesocorticolimbic pathway) and 
tuberoinfundibular systems. The nigrostriatal and mesocorticolimbic pathways, which originate 
from the substantia nigra and ventral tegmental area (VTA) in midbrain, respectively, are reviewed 
below. The tuberoinfundibular pathway originates in the the hypothalamus and influences the 





system, DA also regulates physiological functions in the periphery such as cardiovascular functions, 
hormonal regulation, and renal function12. 
It takes two wiring diagrams to fully appreciate DA circuitry in the basal ganglia and 
mesolimbic pathway and its crucial role in neurophysiological functions. Simplified diagrams are 
shown (basal ganglia [Figure 1-1b], mesolimbic pathway [Figure 1-1c]). The basal ganglia circuitry 
is centered around the striatum, which receives DA input from the substantia nigra via the 
nigrostriatal pathway. The striatum, so called because of its appearance, serves as a relay point 
Figure 1-1 Dopamine neurotransmission and its involvement at the anatomical level. 
(a) Four major DA pathways in the brain are highlighted. Neuromodulation by DA in basal 






amongst various input and output regions.  The structure is comprised of roughly three types of 
neurons: medium spiny neurons (MSN), GABAergic interneurons, and cholinergic interneurons, of 
which MSN makes up ~95%. MSN receives inputs from cerebral cortex, thalamus, as well as other 
interneurons in the striatum and projects inhibitory GABAergic afferent to the globus pallidus (GP) 
as well as the substantia nigra. Among its functions, basal ganglia circuitry is vitally involved with 
motivation and voluntary movement. 
The mesolimbic pathway, on the other hand, plays a significant role in reward and desire. 
In this pathway, inputs are integrated into the nucleus accumbens (NAc), a nucleus in the ventral 
striatum. Originating from the VTA, mesocorticolimbic DA neurons project onto numerous 
structures – hippocampus, amygdala, medial prefrontal cortex (mPFC), NAc and ventral pallidum. 
MSNs in the NAc receives excitatory glutamatergic innervations from hippocampus, amygdala, and 
mPFC and send projections to the ventral pallidum by MSNs. The ventral pallidum sends inhibitory 
GABAergic projections to thalamocortico reentry loops and to the brainstem motor outputs.  
Based on the expression patterns of DA D1- and D2-like receptor subtypes, MSNs are 
categorized into two distinct groups. The MSNs that project to the GP and the substantia nigra 
comprise a direct striatonigral pathway that expresses the D1 receptor almost exclusively. The 
other MSN population projects to the lateral globus pallidus (GPe) and selectively expresses D2 
receptors comprising the indirect striatopallidal pathway. Coordination of the two pathways is well 
characterized in animal models of movement disorder such as Parkinson’s disease in which the 
direct pathway dictates the excitatory signal and the indirect pathway dictates the inhibitory 
signal13. D1 and D2 receptors are expressed within these two discrete neuronal pathways. Recent 





reporter proteins driven by the promoters of either the D1 or the D2 receptor genes illustrate a 
clear distinction between the two DA receptor populations and also sheds light on the complex 
molecular and anatomic interactions between  DA receptor expression and distinct neuronal 
pathways14.  
 Besides Parkinson’s disease, abnormalities of DAergic neurotransmission have been 
implicated in schizophrenia. Given that the unifying property of all antipsychotic drugs’ clinical 
efficacy is their inhibitory action on D2 receptors, it was originally proposed that schizophrenia’s 
etiology was based on dysfunction of DAergic neurotransmission. More recently, it was 
demonstrated that the striatum has increased DA activity relative to other brain regions1. 
However, an increasing body of evidence from a variety of studies including brain imaging and the 
related animal model studies present a more nuanced picture suggesting that rather than simple 
hyperactivity, there is likely a complex pattern of both hypo- and hyper-function in distinct parts of 
the brain. This is especially important in light of the fact that currently available antipsychotics do 
not improve negative and cognitive symptoms. Briefly, while D2 receptor-mediated hyperactivity 
in the striatum is believed to contribute to the positive symptoms in schizophrenia (i.e. delusions 
and hallucinations), hypofunction of the prefrontal cortex (PFC) is thought to contribute to 
negative and cognitive symptoms.  
Dysregulation of DA in schizophrenia shows the central role of DA function in the striatum 
and the possibility of modulating DAergic tone as a rationale for therapeutics. To further 
characterize the relationship between DA and brain anatomy, we will review DA 






Molecular underlining of DA system 
DA neurotransmission largely fits with the conventional model of synaptic function such as 
the one seen in glutamatergic synapse10. DA is released from presynaptic DAergic neurons by 
action potentials and a calcium-dependent vehicle fusion process. After diffusion in the synaptic 
cleft, DA binds to the DA receptors at either the presynaptic side (therefore autoreceptors) or 
postsynaptic side. Autoreceptors are mostly the short variant of D2 receptors (D2short) and upon 
activation they inhibit further presynaptic DA release by activating G protein inward rectifying 
potassium channels (GIRKs)15 as well as other channels16, 17 that subsequently change the 
membrane potential and neural firing rate. They also inhibit DA synthesis via Gi dependent 
mechanism18. There are two groups of DA receptors on the postsynaptic side – D1-like and D2-like 
receptors. D1-like receptors consist of D1 and D5 DA receptors and D2-like receptors consist of D2, 
D3, and D4 DA receptors. As mentioned in the description of MSNs, these two groups of DA 
receptors are largely expressed in separate subsets of neurons with the  exception of MSNs 
reported in the NAc thought to express both D1 and D2 receptor 14. 
DA receptors are class A G protein-coupled receptors that can trigger multiple lines of 
signaling events upon ligand-mediated activation. While D1-like receptors are excitatory, D2-like 
receptors are inhibitory for GABA release from the MSNs expressing the respective receptors. The 
extent of activation is mediated via G protein and voltage gated calcium channel-associated 
processes19-21. The released GABA will feed into the aforementioned basal ganglia and 
mesocorticolimbic pathways. Meanwhile, extrasynaptic DA gets taken up by dopamine transporter 






Despite the overall similarities outlined above, DA neurotransmission also differs from 
conventional synaptic function in several points. First, besides the prototypical axonal DA release 
sites in the striatum, there are somatodendritic release sites in midbrain and those lack clear pre- 
and postsynaptic specialization such as postsynaptic densities. Second, in many striatal neurons 
(up to 70%22) apposing to the axonal DA release sites, postsynaptic specialization seems to be 
lacking17. Third, due to the spatial separation between the release sites and location of DAT and 
DA receptors, the temporal response tends to be slower. In addition, reuptake rate of DAT is much 
slower than other neurotransmitter reuptake transporter (2-5 vs. 35 molecules s-1 transporter-1 
between DAT and glutamate transporter17), which makes the response time of the receptors even 
longer. Despite its slow turnover rate, DAT has been well characterized as a binding target for 
drugs of abuse (e.g. amphetamine and cocaine) in different model organisms23-25. 
 
DA receptors and interacting molecular machinery components 
DA receptors are the principal mediators of all the physiological effects described so far. 
Originally based on the adenylyl cyclase (AC) coupling, D1-like receptors stimulate AC activity 
therefore increasing cyclic AMP (cAMP), while D2-like receptors inhibit ACs12. Later, D1 and D5 
receptors were found to couple to Gs/olf G proteins, which activate ACs in contrast to D2, D3, and 
D4 which were found to couple to Gi/o family of G proteins (i.e. Gi1, Gi2, Gi3, Goa, Gob), that 





Owing to their similarities in agonist selectivity, D1 and D5 receptors share 80% homology 
and D3 and D4 are 75% and 53% homologous to the D2 receptor respectively26. D1 and D5 
receptors do not contain any introns in their coding regions. However, D2, D3, D4 receptors have 
several introns and as a result have splice variants. Particularly for D2, two isoforms have been 
identified. D2long has an extra 29 amino acids in the third intracellular loop compared to D2short. 
As highlighted in the description of the direct pathway, D1 receptors are highly expressed 
in the nigrostriatal and mesocorticolimbic regions, namely the substantia nigra, caudoputamen 
(CPu) of striatum, thalamus, hypothalamus, NAc, amygdala, hippocampus, cerebellum, olfactory 






levels in the MSNs of the caudate nucleus and nucleus accumbens. Low level D5 receptor 
expression is also found in the substantia nigra, hypothalamus, the hippocampus, the entorhinal 
cortex, the dentate gyrus, the cingulated cortex, prefrontal cortex12, 26. 
Delineating the indirect pathways, D2 dopamine receptors are highly expressed in the 
nigrostriatal and mesocorticolimbic regions, namely the substantia nigra, VTA, CPu of striatum, 
hypothalamus, NAc, amygdala, hippocampus, olfactory tubercle, septum, and frontal cortex12, 26. 
D2short receptors predominate in presynaptic DA neurons where they function as autoreceptors 
while D2long receptors are on the dendritic postsynaptic end. Therefore, these differences in 
receptor synaptic localization suggest differences in their respective physiological roles. Compared 
to D2, the D3 receptor expression pattern is quite limited. It is preferentially expressed in the shell 
of NAc and the olfactory tubercle with lower levels of expression in the substantia nigra, VTA, CPu 
of striatum, the hippocampus, the septal area, and in cortical areas12, 26. The expression level of D4 
receptor is the most limited amongst all the DA receptors with very low expression in the 
substantia nigra, globus pallidus, thalamus, hypothalamus, amygdala, hippocampus, and frontal 
cortex. 
It should be also mentioned that both D1-like and D2-like receptors have high and low 
affinity states corresponding to G protein pre-coupled and uncoupled states27. Half maximum 
binding capacity for the high affinity state is reported to be between 10-180 nM for both D1 and 
D2 receptors in striatum28, 29 showing good match with physiological quantal vesicular release of 







DA receptors belong to class A family (rhodopsin-like) G protein-coupled receptors 
(GPCRs) based on sequence homology of conserved motifs. GPCRs comprise a superfamily of more 
than 800 proteins with canonical seven transmembrane domains that are associated with guanine 
nucleotide binding proteins (G proteins). Based on the association between the receptor and G-
proteins, various extracellular signals (e.g. light, neurotransmitters, peptide hormones, and 
enzymes) are transduced into intracellular signals by different species of G proteins (reviewed 
later). Therefore, the DA receptors consist of a ligand binding area and G protein coupling area and 
these two sites are structurally linked. It should be mentioned here that the structure and function 
relationship of D2 receptor can now be studied with the recent advent of antagonist-bound D3 
receptor crystal structure30 as well as a whole series of related GPCRs in different states31. 
Amongst the DA receptors, there are significant differences in the length of the 3rd intracellular 
loop (IL3) and C-tail (Table 1-1). IL3 of D2-like receptors comprise approximately 30% of the entire 
length whereas D1-like receptors have a much shorter IL3. The C-tails of D1-like receptors, on the 
other hand, are much longer than D2-like receptors. Together these differences are thought to 
have an impact on receptor functions such as G protein coupling and trafficking12, 26.  
 
Dopamine receptor signaling 
G Protein-dependent signaling 
Like for other GPCRs, prominent downstream signaling activated by DA receptors are 





α, β, and γ subunits. In the absence of agonist activation of the receptor, the α-subunit is bound to 
GDP and in a close formation with βγ-complex, which is often referred to as an inactive complex. 
Upon agonist binding, a series of conformational changes within the receptor transduces further 
conformational changes to the associated heterotrimeric G protein. This event is thought to lead 
to GDP release, GTP binding to the α-subunit, and the dissociation of the complex into a free α-
subunit and the βγ-complex. When GTP gets hydrolyzed to GDP in the α-subunit (or exchanged to 
free GDP), the GDP-bound α-subunit binds again to the βγ-subunit complex and form the inactive 
G protein complex. Both the α-subunit and the βγ-complex can separately activate effector 
proteins initiating signal transduction events. 
There are 16 subtypes of α-subunits which are classified into four groups based on 
sequence homology – Gs, Gi, Gq, and G12. Gs and Gi regulate AC positively or negatively, 
respectively, to control cAMP production. Gq activates phospholipase C (PLC) (particularly β family 
(PLCβs)) and promotes cleavage of phosphatidylinositol bisphosphate (PIP2) into inositol 
triphosphate (IP3) and diacyl glycerol (DAG). IP3 mobilizes ER calcium stores via ligand gated 
calcium channel IP3 receptor while DAG can activate protein kinase C (PKC) separately. G12 
activates RhoGTPase nucleotide exchange factors32. Although their cognate coupling α-subunits 
are thought to be Gs family and Gi/o family proteins for D1-like and D2-like receptors, 
respectively, (Table 1-1), Gq33/Go34/G1635 coupling to D1 and G1635 coupling to D2 have also been 
suggested. 
β- and γ-subunits are comprised of 5 and 12 subtypes. Based on the mRNA expression 
level in different cell types as well as the structural relation between β- and γ-subunits, many of 





β5, γ2, γ7, γ11 are particularly abundant36-38. βγ complexes are reported to couple with PLCβs39, G 
protein coupled receptor kinase 2 (GRK2)40, AC isoforms41, inwardly rectifying potassium channels 
(GIRK)15, and N-type calcium channels42. 
G proteins are also regulated by accessory proteins such as activators of G protein 
signaling (AGSs)43 and regulators of G protein signaling (RGSs)44 that influence GTP/GDP binding, 
GTP hydrolysis, or G protein subunit interactions independent of GPCR interaction. AGS proteins 
facilitate the rate of GDP to GTP exchange, whereas RGS proteins accelerate the rate of GTP 
hydrolysis in the α-subunit of G proteins, therby regulating the duration of G protein activation 
either positively or negatively. 
Molecular mechanisms of G protein coupling to the receptor and subsequent activation of 
the heterotrimeric G protein are not fully understood despite the mostly accepted G protein 
activation cycle shown above. Although current assay approaches, mostly resonance energy 
transfer between fluorophore-fused proteins, have made a great advance, there needs to be more 
investigation in elucidating the dynamic nature of protein-protein interactions and conformational 
changes within the proteins. For example, the extent of receptor-G protein precoupling state is 
under debate as the interaction can also result in free collision45, 46. One functional consequence of 
the precoupling would be the basis for the differences seen in ligand affinity states of the 
receptors, particularly D1R and D2R1, 27. The presence of the pre-associated Gα subunit stabilizes 
the receptor in a certain conformation amenable to better ligand binding. Another important 
question is the conformational status of activated Gα subunit. Although subunit dissociation in the 
heterotrimer (i.e. Gα and βγ dissociation) has been proposed as the necessary step for functional 





suggests that the G protein heterotrimer may not dissociate upon activation and the associated 
heterotrimer can still signal45, 46. This provokes an idea that functional Gα can be in different 
forms. Besides the heterotrimer-associated state, the conformational state of the Gα itself could 
also be different, which could give rise to differences in functional effector coupling. Indeed 
differences in the kinetics of Gs-dependent signaling were shown between adenosine A2A 
receptor and β1 adrenergic receptor. In Chapter 3, this point will be addressed extensively in 
comparison of Gs protein conformations between adenosine A2A receptor and DA D1 receptor. 
 
Receptor regulation by arrestins/GRKs  
Following prolonged ligand stimulation, GPCRs are desensitized to attenuate continued 
signaling. This process involves blockade of further G protein activation and subsequent receptor 
internalization, both of which are mediated by arrestin adaptor proteins. First, activated receptors 
are phosphorylated at intracellular amino acid residues by GRKs and arrestins are recruited to 
them. The physical interaction between the phosyphorylated receptor and arrestin prevents G 
protein coupling and activation. Then, another adaptor protein β-adaptin and clathrin are 
recruited to the receptor-arrestin complex, which is subsequently internalized into an endocytic 
clathrin-coated pit. After endocytosis, receptors can either recycle back to the cell surface or get 
degraded via lysosomes48, 49. Amongst the seven GRK subtypes, GRK2-6 are well-expressed in most 
tissues and of four subtypes of arrestins, arrestin 2 (β-arrestin 1) and arrestin 3(β-arrestin 2) are 
the most highly expressed subtypes. This suggests that they are involved in DA receptor regulation 
in the striatum.  Other protein kinases such as protein kinase C (PKC) have also been shown to 





has been identified for D1 receptor52, the fate of D2 receptor can to be either recycling53 or 
degradation54. GRKs and arrestins can also initiate G protein-independent signaling events. For 
instance, receptor-bound arrestins interact with Akt and protein phosphatase 2A (PP2A) to 
activate subsequent glycogen synthase kinase 3 (GSK3) signaling55. 
 
Downstream of G protein 
The level of cytosolic cAMP regulated by D1-like (i.e. Gs-coupled) and D2-like (i.e. Gi-
coupled) receptor activation directly controls the activity of protein kinase A (PKA), making cAMP a 
central regulator of DA receptor-mediated downstream signaling (Figure 1-2). PKA phosphorylates 
and regulates numerous proteins, particularly those controlling membrane potential and gene 





ionotropic glutamate receptors, GABAA receptor, calcium channels and sodium channels and the 
latter include cAMP response element-binding (CREB) transcription factor and extracellular-signal 
regulated kinases (ERKs) of MAP kinase pathway. The NR1 subunit of the N-methyl-D-aspartic acid 
(NMDA) receptor, for example, gets phosphorylated by D1 receptor  following PKA activation and 
this enhances NMDA receptor currents56. On the other hand, D2 receptor activation and 
subsequent PKA inactivation leads to diminished calcium influx through NMDA receptor showing 
opposing electrophysiological effects at MSNs20.  
Amongst the PKA substrates in MSNs, Dopamine- and cAMP-regulated phosphoprotein, 
Mr 32 kDa (DARPP-32) has been investigated extensively. DARPP-32 is a multifunctional 
phosphoprotein that is predominantly expressed in both D1- and D2-positive MSNs. The 
phosphorylation state of DARPP-32 at two key residues determines whether it becomes an 
activator or inhibitor of interacting effectors (thorough phosphorylation events are described in 
Svenningsson et al56.) PKA phosphorylates DARPP-32 at Thr34, thereby converting DARPP-32 into 
an inhibitor of protein phosphatase-1 (PP-1). Cdk5 phosphorylates DARPP-32 at Thr75, in turn 
converting it into an inhibitor of PKA. Thus, DARPP-32 is a dual-function protein, acting as an 
inhibitor of either PP-1 or of PKA. PKA-mediated phosphorylation of DARPP-32 at Thr 34 inhibits 
Figure 1-2 Signaling pathways downstream of D1R and D2R activation. 
AC=Adenylate cyclase, cAMP=cyclic AMP, PKA=protein kinase A, DARPP-32=Dopamine- and 
cAMP-regulated phosphoprotein, Mr 32 kDa, VGCC=voltage-gated calcium channel, GIRK=G 





PP-1. This PP-1 inhibition leads to disinhibition of phosphorylation of the NR1 subunit in 
NMDAR at Ser 89756. 
Apart from PKA mediated signaling, Gβγ complexes initiate their own signaling pathway as 
well. Gβγ complexes, particularly of the pertussis-toxin sensitive Gi/o family containing 
heterotrimers, functionally couple to several different effectors. They bind to GIRKs and gate the 
channels open. As the outcome of this is a hyperpolarizing outward current, the activation of 
GIRKs has an inhibitory effect on the MSNs. Gβγ can also activate PLCβ and induce calcium release 
from ER, and this further activates the calcium-dependent phosphatase calcineurin57. Gβγ also 
negatively regulates N-type calcium channels42. This makes Gβγ a unique calcium-regulating 
component in DA receptor-expressing neurons. 
 
DA regulation of calcium homeostasis 
Calcium triggers a variety of neurophysiological processes. It can regulate neuronal 
electrical activity10 and synaptic plasticity58 and its misregulation leads to pathophysiological 
consequences58, 59. Cytosolic calcium levels can be increased by two mechanisms: calcium entry 
through plasma membrane channels and internal release through IP3 receptors (via Gq-linked 
receptors). These have been well characterized for other neurotransmitters such as glutamate and 
acetylcholine. DA signaling has been typically linked to cAMP regulation and its calcium regulation 
has not been fully understood. Here, the current understanding and importance of the 





Extracellular calcium entry to the cytoplasm is mediated by voltage-gated and ligand-gated 
calcium channels (VGCC and LGCC). This calcium influx at the synapse is a major regulator of 
synaptic plasticity. DA receptor-mediated modulation of these channel activities plays a role in 
synaptic physiology in MSNs. D1 receptor stimulation and PKA activation increase Cav1 L-type 
calcium channel currents. PKA phosphorylation of the NMDA receptor (NR1 subunit) is reported to 
enhance NMDA receptor currents60. The PKA activation also enhances surface expression of both 
AMPA (GluR1 subunit) and NMDA (NR1 subunit) receptors20. Localization and trafficking are also 
affected by a direct interaction between D1 and NMDA receptors61. D2 receptor activation 
decreases dendritic calcium entry through both VGCC and LGCC20, 42. A VGCC inhibition mechanism 
has been suggested to result from direct coupling of Gβγ in the CaV2 channels62. NMDA receptor-
dependent calcium influx, on the other hand, is inactivated in a PKA-dependent manner63.  
Intracellular calcium in neurons is typically released from the ER and mitochondria64, 65. 
However, the GPCR-derived calcium response can be attributed to the ER since it involves PLC 
activation, IP3 production, and subsequent gating of the IP3 receptors, which mainly reside on the 
ER membrane. The relative contribution of influx from the extracellular milieu vs. release from 
intracellular stores is not clear. The calcium concentrations of three distinct locales, the 
extracellular space, inside the cytosol, and inside the ER are: [Ca2+]out = low mM,  [Ca2+]in = low nM, 
and [Ca2+]ER = high µM. Therefore, one might expect calcium entry from the extracellular space to 
be more significant in terms of concentration increase. However, the reality is that the internal 
release is much more robust. The kinetics of LGCC and VGCC opening are transient and in the 
order of milliseconds. This translates to an increase of sub to low µM calcium in the confined area 





much longer and the increase in calcium concentration can reach up to low µM in a much more 
widespread cytosolic space. This is much greater in comparison with the restricted several µm 
radius in the case of extracellular influx. The IP3 receptor, which is not a voltage gated channel, 
can release calcium with more prolonged steady kinetics with abundant IP3 molecules nearby. The 
propagation of the released calcium is mainly by diffusion and occurs on an order of minutes, 
depending on cell type, to subside [Ca2+]in to low nM since it requires pumps to store back calcium 
into the ER and mitochondria. 
As with the influx from the extracellular space, release of calcium from ER stores has been 
linked to synaptic plasticity and protein synthesis as well. These processes are mediated by 
activation of calcium-calmodulin kinases (CaMKs) and DAG-dependent PKC58, 66. The connection 
between DA receptor and PLC activation has been an active topic of discussion since the mid-
1990’s. There have been numerous reports indicating different mechanisms: Gq-coupling to D1-
like receptors33, 67, specifically D5R68, D1R-D2R9 and D2R-D5R69 heterodimers, Gαi70- and Gβγ 
subunit57-mediated PLC activation in D2R, as well as in the purported D2R-ghrelin receptor 
heteromer71. There is also evidence of a “potentiation mechanism” whereby D1R-PKA activation 
stimulates (phosphorylates) the IP3 receptor upon “potentiation” of the IP3 receptor by Gq-PLC 
activation72, 73. In addition, there are other studies reporting the intracellular calcium release 
without addressing the intermediary protein between DA receptor (D1-like receptors74-76, 
specifically D5R77, or D2R75) and PLC. This disparity in the literature may well capture the 
complexity of actual phenomenon, but it may also be based on uncertainties due to the limitation 





mechanism between the DA receptors and PLC and this has become an important component of 
my thesis and will be discussed in Chapter 4. 
Clinically, DA-mediated calcium signaling may play a role in schizophrenia since elevated 
levels of calcium in striatum as well as lower density of calmodulin-positive neurons in prefrontal 
cortex have been reported59, 78. Although the validity is under discussion, these findings correlate 
with the hypo- and hyperfunctions of DA transmission in the corresponding areas reported in 
schizophrenia (see above). Thus, PLC-linked calcium release via DA receptors provides perhaps an 
explanation for up- and down-regulation of intracellular calcium level in the striatum and 
prefrontal cortex.  
 
DA receptor pharmacology 
Pursuit of pharmacological targeting of DA receptors has generated two effective lines of 
therapeutics – anti-Parkinson’s Disease (anti-PD) drugs and antipsychotics. The most prescribed 
anti-PD drug is a DA prodrug L-DOPA. It crosses the blood brain barrier and gets converted to DA 
by DOPA decarboxylase in the DAergic neurons undergoing neurodegeneration. By controlling L-
DOPA dosage, DA in the brain is made available to stimulate the DA receptors in DAergic 
projection areas and alleviates the related motor symptoms. For this reason, it is also referred to 
as a DA replacement therapy. Both pan-DA receptor and D2 receptor agonists are also used as 
anti-PD drug while D1 receptor agonist dihydrexydine (which also has D2 receptor activity) had 





In contrast to DA replacement therapies, antipsychotics have been used to dampen DA D2 
receptor signaling. These drugs can be largely categorized into first generation (or typical) and 
second generation (or atypical) drugs. They improve positive symptoms of schizophrenia by 
working as D2 receptor antagonists/inverse agonists and downregulating the aforementioned D2-
mediated signaling events1. The first generation drugs were introduced in the 1950’s and may 
cause more pronounced extrapyramidal side effects. The second generation drugs were 
introduced in the 1990’s and they are less likely to cause extrapyramidal symptoms presumably 
because they bind to 5-HT receptors as well. The atypicals were developed in the hope of  
improving on negative and/or cognitive symptoms, but that has not been clearly demonstrated as 
seen in Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) multi-center evaluation 
trial79, 80. If anything, the trial made it apparent that with little exception there were few 
discernible advantages between the newer, more expensive second generation drugs and the 
much less expensive first generation typical antipsychotic drugs. Moreover, the trial highlighted 
one of the main problems with drug adherence – significant weight gain, particularly with atypicals 
like olanzapine80. The atypical drug aripiprazole may indeed be differentiated from other atypical 
drugs from two different points of views. First, it has been proposed that aripiprazole works as a 
D2 receptor partial agonist and can address both hypoactive and hyperactive DAergic 
transmission. Thus, it can “stabilize” the DA system81. Secondly, aripiprazole is proposed to have 
functionally selective properties at different signaling pathways. It works as a partial agonist to Gi-
mediated cAMP inhibition and an antagonist to GIRK activitiy81 compared to other antagonists that 
block both pathways. This idea of subdividing the intrinsic efficacies into distinct parameters 
shines light on aripiprazole as a unique atypical antipsychotic (also referred to as a “third 





pharmacological analyses with different batteries of assays seem necessary to characterize each 
ligand. Perhaps, the previous literature may have to be reevaluated to determine the efficacy of 
drugs in different signaling outlets. One particular interest in the field is that a functionally 
selective drug can narrow the targeted pathways, thereby avoiding stimulating or blocking other 
pathways that lead to unwanted side effects. The concept of functional selectivity is reviewed 
next. 
   
Functional selectivity of receptor signaling 
Receptor activation can lead to triggering of more than one signaling pathway measurable 
by a set of different assays. The difference amongst ligands then refers to the difference of a 
pattern of activation in the individual respective pathways. For instance, ligand X can be a full 
agonist at pathway A and an antagonist or weak agonist at pathway B. Ligand Y can have a 
different profile such that it is a partial agonist at pathway A and full agonist at pathway B (Figure 
1-3). This concept may seem at odds with the ‘classical’ intrinsic efficacy idea, where the strength 
of an agonist’s capacity to activate signaling has to be reflected in all the pathways. In other 
words, if a ligand is a partial agonist, then the partial intrinsic efficacy should be observed in all 
pathways. However, the careful study and comparison of different pathways that have been 
enabled by modern pharmacological approaches have demonstrated that individual signaling 
pathways are not all modulated in a similar manner. Functional selectivity has many synonyms 
(e.g. biased signaling and protean agonism) but “functional selectivity” seems the most widely 





There is ample evidence for different types of functional selectivity in the literature82. A 
prominent example can be found in D1 receptor. The Mailman group has tested three structurally 
distinct D1 agonists for their ability to stimulate cAMP activation and receptor internalization (i.e. 
arrestin activation)83, 84. Among them, A77636 showed full agonism for cAMP production much like 
dinapsoline, but it demonstrated faster and more significant levels of internalization compared to 
DA or dinapsoline. This rapid internalization is consistent with a previous report on rapid motor 





that is biased toward internalization, likely because of more efficient arrestin recruitment as 
compared with DA. 
 
GPCR dimerization 
 In light of the different mechanistic bases for functional selectivity, allostery between two 
receptors can be thought of as one possiblity. Studies have shown that class A GPCRs can dimerize 
and even oligomerize in both heterologous cells and native tissue4, 86-92. This is highlighted by 
striking visualization of rhodopsin oligomer rows in mouse optic disc via atomic force microscopy93, 
94. This phenomenon is not only seen among homogeneous populations of receptors (i.e. homo-
dimer/oligomerization) but also between two different kinds of receptors (i.e. hetero-
dimer/oligomerization) including subtypes of opioid receptors95, different glycoprotein hormone 
receptors86, and others3, 4, 96-99. In particular, the class C GPCR, γ-aminobutyric acid receptor B 
(GABAB) receptor dimer (i.e. GABAB1R-GABAB2R) is an elegant representation of 
heterodimerization for two reasons. First since it involves necessary masking of ER retention signal 
in the C-tail after interaction of its coiled-coiled domains in order to allow the dimerized receptors 
Figure 1-3 Concept of functional selectivity in GPCR signaling. 
 (a) A prototypical agonist activation results in activation of G protein and arrestin coupling. (b) 
A G protein-biased agonist would trigger more G protein activation and less arrestin 
recruitment compared to the prototypical agonist. (c) An arrestin-biased agonist would trigger 






to reach the cell surface100. Second since it requires transactivation of dimers where one 
protomer, GABAB1, binds ligand and another protomer, GABAB2, interacts with G protein100. 
Nevertheless, the first hurdle to understanding dimer-dependent biological effects is the lack of 
tools to differentiate downstream crosstalk and dimer-specific signaling such as that seen in 
GABAB receptors (Figure 1-4). This point will be the main focus of Chapter 2. There are many other 
questions surrounding dimerization and higher order complexes. For example, we do not know 
which of the GPCR forms are functionally active or what the minimum functional unit is for Gα 
coupling.  





One example of GPCR complex formation comes from chemokine receptors. Chemokines, 
a class of cytokines, through their actions at chemokine receptors induce chemotaxis of leukocytes 
to inflammatory sites and are involved in other biological activities such as angiogenesis and 
cancer metastasis101. Significantly, chemokine receptors recognize human immunodeficiency virus 
(HIV) viral coat proteins, facilitating initiation of cellular entry of the virus101. Recent literature as 
well as our own study have shown that chemokine receptors heterodimerize (e.g. CCR2/CCR5102, 
CCR2/CXCR4103) and even heterooligomerize and they remain functionally active104. 
Classical GPCR pharmacology has assumed that class A GPCRs exist functionally in the 
monomeric form. Although there have been studies suggesting that the monomer is the minimal 
functional unit for some receptors in artificial settings105-107, these findings have to be taken with 
caution. Such studies are based on the confined expression of single receptor, therefore excluding 
the possibility of heteromer interaction. In other words, while functional as a monomer, in 
physiological settings there are many other receptors present in proximity because of structural 
platforms like microdomains108, 109. Thus, monomers may not be the minimal functional unit for 
certain receptors in actual cells110. Moreover, when two GPCR protomers interact, activation of 
downstream signaling no longer involves a simple single input / output behaving in a causal 
relationship. That is, the activation of one receptor not only triggers a signal transduction pathway 
downstream of itself (i.e. cis-activation) but now also affects the interacting GPCRs (i.e. trans-
activation) either through downstream crosstalk or directly through physical interactions between 
protomers. 
Allosterism is an alteration of function at a distance from the site of interaction through a 





bind to site other than the orthosteric binding site (OBS) but act at a distance to alter ligand 
binding to the OBS or the imact of ligand binding to this site111-113. When considering dimers, the 
allosteric effects can be induced by one of the receptors acting on the other, and the downstream 
signaling may differ from activation of the individual receptors alone. One example of how this has 
an impact in pharmacology would be cooperativity of GPCRs. Here, crosstalk between two or more 
receptors causes an allosteric change after a single ligand binds to one of the receptors. The 
thyrotropin receptor (TSHr) exhibits negative cooperativity between the homodimer, in which 
ligand binding of one protomer reduces ligand binding in the other protomer114. There are more 
ramifications if the interaction is heteromerization between two different kinds of GPCRs. For 
instance, it may cause a change in ligand affinity in one of the GPCRs, or it may modulate 
downstream signaling effects of one receptor while a ligand binds to the other receptor. There 
have been many studies addressing this issue in chemokine receptors and opioid receptors88. 
Another form of speculated signaling change in heteromerization is the Gα protein 
coupling switch. While two receptors interact at the cell surface, coupling of Gα to its respective 
receptors may be affected by the receptors’ allosteric changes. Studies have suggested that 
certain heteromer pairs may undergo coupling to their non-cognate G proteins115. For example, 
heteromerization between δ-opioid receptor (DOR) and µ-opioid receptor (MOR) is reported to 
couple to Gz instead of their cognate Gi116. Heteromerization between endocannabinoid receptor 
1 (CB1) and D2 DA receptor switches CB1 coupling from Gi to Gs upon co-activation of D2R117. Also 
notably, heteromerization between D2-D1 DA receptors is reportedly found to activate Gq/11-
mediated pathway, a switch from Gi (D2) or Gs (D1) coupling9. Although very attractive as novel 





of G-protein coupling are controversial with conflicting reports in the literature. MOR is reported 
to couple with pertussis toxin insensitive Gz118, and CB1 reportedly couples to Gs without any 
coexpression of other receptors119-122. The D2-D1 heteromer also needs careful analysis and the 
main argument can be broken down to two parts. First, it is possible, as discussed above, for 
calcium mobilization to result from receptor actiation through multiple pathways that need not 
involve Gq, and the purported dramatic coupling switch might be explained by alternative PLC 
activation (see previous section). Second, the extent of D2-D1 coexpression in MSNs has been 
somewhat controversial and the receptors at least in the dorsal striatum are thought to be 
expressed in distinct cells14, 28, 123-132. Therefore, the level of colocalization between the two 
receptors and their propensity to interact in vivo needs to be investigated more carefully. 
Homo-/hetero-oligomerization of GPCRs has also been under debate because it is difficult 
to prove that oligomers function in physiological settings. Membrane preparations or 
heterologous expression systems might promote the aggregation or artificial interaction of 
proteins and may not reflect the physiological condition133. However, some studies have provided 
evidence for homo- and/or hetero-dimers or oligomers as a functional complex in class A GPCRs87, 
134-137. Moreover, in hetero-oligomers the above-mentioned allosterism can play an increasingly 
complex role because of the increased number of interacting receptors and intracellular binding 
partners (e.g. heterotrimeric G-protein). One allosteric model was demonstrated in our recent 
chemokine receptor study, in which specific antagonists (TAK-779 or AMD3100) of one receptor 
(CCR5) lead to functional cross-inhibition of the other receptor (CXCR4)104. 
In order to better understand the biology of neurons expressing D2-like receptors, D2R 





example, it has been shown that D2R can form a heteromer with several different GPCRs including 
other dopamine receptor subtypes5-7, adenosine receptor 2A (A2AR)138, 139, and cannabinoid 
receptor 1 (CB1)117, 140, 141, as well as with the ligand gated ion channel NMDA receptor subunit 2B 
(NR2B)142. In addition, interactions elsewhere in the brain have been proposed for D2 with 
somatostatin receptor 5 (SSTR5)136 and ghrelin receptor (GHSR1a)71. Other candidate receptors 
(e.g. opioid receptors135 and chemokine receptors143, 144) may also interact with D2 receptor based 
on their known localization in DA receptor expressing neurons. For each receptor interaction, 
allosterism of the partner receptor may play an important role in modulating ligand binding 
and/or signal transduction by the second protomer (Figure 1-5b). Heteromers have captured the 
interest and imagination of pharmacologists because of the potential for developing better 
therapeutics by targeting receptor complexes that may be expressed differentially in different 
regions or may have more nuanced signaling than possible with single protomers. Another 
potential target that will not be discussed here is the putative heteromer formed by a serotonin 5-
HT2A receptor and metabotropic glutamate receptor 2 (mGluR2) 145, which may play a role in 
antipsychotic drug effects. Ultimately, given their potential in therapeutics and to deepen our 
understanding of physiological receptor interactions, the existence and function of hetero-






Figure 1-5 Dopamine neurotransmission at molecular level and relevance of receptor 
heteromerization. 
(a) DA-containing vesicles are exocytosed after triggering of an action potential and the released 
DA binds to activate both postsynaptic and presynaptic D2 receptors. Presynaptic receptors 
function as autoreceptors inhibiting further DA release. DA signaling is further deactivated by 
clearance of extrasynaptic DA molecules by dopamine transporters. (b) Heteromerization of D2R 






A recent study of A2AR-D2R colocalization in the striatum146 suggests that this heteromer 
pair exists in close proximity in vivo, suggesting the possibility of direct interactions apart from 
downstream crosstalk effects. A2AR’s endogenous ligand adenosine is considered as a 
neuromodulator released from neurons as well as glial cells due to ATP metabolim147. The receptor 
is uniquely enriched in the striatum and nucleus accumbens38 and it plays a role in neurological 
and psychiatric functions148. Caffeine is an antagonist of the A2A receptor. Other A2A antagonists 
have been intensely studied as anti-Parkinsonian therapies149. A2AR is a Gs-coupled receptor and 
reports suggest that Gs activation can be modulated positively150 or negatively151 by D2R 
activation. In addition, A2AR activation counteracts D2R signaling152. Given that A2A activates Gs 
and D2 activates Gi, there is ample opportunity for crosstalk without requiring heteromerization 
but other evidence suggests a possible role for this heteromer in signaling, making it an appealing 
target for manipulating MSN function. In vitro work has argued that the A2AR-D2R 
heteromerization depends on an electrostatic interaction between an arginine-rich epitope in the 
N-terminal segment of the IL3 of the D2 receptor and a phosphate group in the C-terminus of the 
A2A receptor153, 154. 
In relation to my thesis work, among the different heteromer pairs mentioned above, I 
primarily focused on the D1R-D2R heteromer pair because of its potential importance in MSN 
signaling (particularly calcium signaling) and the degree of controversy surrounding the receptor 
colocalization status as well as the coupling switch hypothesis mentioned above. I have also 
carried out preliminary studies of G protein coupling in the A2AR-D2R heteromer in the process of 






Questions asked and answered in my thesis 
The thesis is organized mainly by chronological order over the course of my research in Dr. 
Javitch’s lab. First in Chapter 2, using biophysical assays (i.e. BRET) we set out to investigate the 
significance of GPCR dimer function especially at the immediate effector coupling level. The 
motivation behind this was to develop an approach to study signaling from a defined receptor 
heteromer, without the complexity added by concurrent homomeric signaling. Numerous pairs of 
receptors have been reported to interact, but other than in exceptional cases86, 100 it is not possible 
to conclude that signaling crosstalk results from receptor interaction and not downstream 
integration of signaling.  Based on the proposed functional relevance in MSN physiology, we used 
a putative DA D1 and D2 receptor dimer pair as a model to investigate the role of allosteric 
interaction between the two receptors in mediating receptor-effector coupling changes. 
Additional work on G protein coupling to D2 heterodimers as well as studies of DA receptors 
expressed alone revealed an unexpected lack of evidence for Gq-coupling. 
In Chapter 3, our attempts to study another dimer pair of relevance in the striatum, the D2 
and A2A receptor dimer, required the development of a new set of BRET biosensors. This work 
allowed us gain a glimpse into the conformational changes in heterotrimeric G proteins and 
uncovered differences in the Gs changes induced by D1 receptor and A2A receptor. We also 
developed a working Gs protein sensor for A2A-D2 heterodimers. 
The lack of Gq-coupling in DA receptors made us question the proposed mechanism by 
which DA promotes Gq activation at a D1-D2 heteromer, leading to PLC activation. In Chapter 4, 
we investigated the extent of colocalization between D1 and D2 receptors in rodent striatal brain 





colocalized in vivo, suprisingly even in the very limited population of neurons in which they are 
coexpressed. Given the lack of Gq coupling to DA receptors and the absence of the D1R-D2R 
colocalization, I have more recently carried out preliminary experiments in which I have begun to 
explore alternative mechanisms for DA-mediated PLC activation. Results showed that in cells 
expressing only D1 or D2 there was PLC-dependent DA-mediated calcium release that may be 
mediated, at least in part, by the Gβγ subunit. 
 
Principles of methodologies 
Bioluminescence resonance transfer (BRET) assays and intracellular calcium imaging were 
heavily used in the thesis. Underlying principles of these two assays are reviewed here. 
 
BRET 
There has been an ongoing challenge to accurately evaluate protein-protein interactions. 
This is especially relevant to evaluating GPCR dimerization status as well as G protein coupling to 
GPCRs. Experimental techniques such as co-immunoprecipitation do not reflect actual plasma 
membrane localization since this biochemical approach involves detergent extraction that often 
interferes with such physical interactions. Even with a surface labeling technique (e.g. 
biotinylation), which may restrict the spatial resolution of cell surface receptor localization, 
temporally dynamic associations and dissociation of receptors cannot be addressed. Therefore, to 





resonance energy transfer (RET) techniques are better-suited. Nevertheless, RET results should 
also be analyzed carefully for reasons described below. 
RET is an energy transfer caused by the dipole-dipole interaction between donor and 
acceptor fluorescent molecules in close proximity to one another and is measured by fluorescence 
emission from the acceptor after illuminating the donor. The difference between two commonly 
used RET techniques is that fluorescence RET (FRET) uses a fluorescence molecule as a donor 
which relies on initial laser excitation while BRET uses a bioluminescence emitting donor thus not 




[1 + ( 𝑟𝑅0
)6]
 
𝑅0 = [𝑐 ∙ κ2 ∙ 𝑄𝐷 ∙ ε𝐴 ∙ 𝐽(λ)]1/6 
where energy transfer or RET efficiency (E) inversely correlates to the distance (r) between donor 
and acceptor by the 6th power. R0 is known as the Förster distance where RET efficiency is 50% of 
the maximal efficiency. Therefore, RET approaches 1 if r < < R0 and 0 as r > > R0. R0 theoretically 
varies among different pairs of fluorescent proteins and is determined by multiple different 
factors: alignment of donor and acceptor fluorescent dipoles (κ2), overlap of donor emission 
spectrum and acceptor excitation spectrum (𝐽(λ)), donor quantum yield (𝑄𝐷), acceptor absorption 
coefficient (ε𝐴), and a constant (𝑐). In plain language, the RET can change both by the relative 





Schematically, there are three biophysical techniques used in this work: BRET, bimolecular 
complementation, and complemented donor acceptor RET (CODA-RET). First, BRET involves an 
energy transfer between a bioluminescent donor molecule and a fluorescent acceptor molecule. 
Technical overview and related precautions are discussed in greater detail elsewhere156, 157. In this 
thesis, the bioluminescent donor is a Renilla luciferase-tagged protein and the fluorescent 
acceptor molecule is a protein tagged with a variant of yellow fluorescent protein (YFP). When a 
substrate, coelenterazine, is added to the luciferase-tagged protein (as opposed to illuminating 
laser in FRET), it luminesces and energy transfer occurs to the donor tagged with YFP variant. The 
fluorescence emission from the acceptor is measured by a fluorescence reader at a designated 
wavelength. Typically, the energy transfer can only occur if the two molecules are within 100 Å46. 
Thus, the interaction of two receptors can be measured by the luminescence/fluorescence 
transfer efficiency. BRET is chosen over FRET because there are two known drawbacks for FRET: 1) 
fluorescence of the acceptor fluorescent protein due to illumination that is intended to excite the 
donor fluorescent protein; 2) photobleaching of fluorescent proteins caused by repeated 
illumination. 
The second class of technique is bimolecular complementation of either luminescent or 
fluorescent proteins158-160. The basis of complementation is that the emitter or acceptor protein is 
split into two parts and expressed separately as fusion products with GPCRs or G-proteins. The 
split partners will form a functional full length and therefore fluorescent protein only if they 
interact (i.e. functional luminescence protein or fluorescence protein). Thus, upon 
complementation of luciferase, for instance, one half of luciferase (L1) and the other half (L2) 





Two parts of the split protein (i.e. L1 and L2) can be tagged to the C-termini of two different 
receptors and the receptor interaction can be observed as the bimolecular complementation of 
either a luminescent-emitting luciferase or fluorescent protein (Figure 1-6a). One criticism for the 
complementation is the possibility that the interaction between the split proteins forces 
dimerization independent of the receptor interaction. However, this phenomenon can be 
controlled for by testing a complemented pair of two unrelated receptors known not to interact or 
by a parallel experimental procedure such as TR-FRET. 
Finally, the third class of RET is higher order BRET, which we have termed complemented 
donor acceptor RET (CODA-RET). It is a combination of above two methods. That is, there can be 
up to four different receptors and/or G-proteins tagged with split luminescence and fluorescence 
proteins (i.e. luciferase1/luciferase2 and Venus1/Venus2). In this case, there is fluorescence only 
when four of the tagged proteins are sufficiently close to be within the Förster distance for energy 
transfer. This higher order BRET allows the detection of trimers and tetramers by direct 
interaction. Furthermore, even higher order oligomerization can be detected by combining 





chemokine receptors was verified104. A major motivation for developing CODA-RET was to 
incorporate biosensors (e.g. G proteins fused to fluorescent proteins) to the receptor dimers with 
bimolecular complementation (Figure 1-6b). By coexpressing L1 fused and L2 fused receptors as 
well as Venus-fused G protein sensor, drug-induced G protein coupling to the dimer complex can 
be measured specifically. These BRET assays are utilized to assess coupling of D2 dimers (both 
homomers and heteromers) with G proteins. 
Calcium imaging 
Fluorescent calcium indicator dyes were used in my thesis both in heterologous cells and 
primary culture. A wide array of other techniques are available to measure calcium 
concentrations. Particularly, one approach considered is to transfect cells with aequorin161, which 
Figure 1-6 Building blocks of CODA-RET. 
 (a) N-terminal (amino acids 1-229) and C-terminal (amino acids 230-311) pieces of luciferase 
can complement after separate expression. Using this bimolecular luciferase complementation, 
one receptor fused with N-terminal end of luciferase and another fused with C-terminal end of 
luciferase can form complemented luciferase upon close interaction of the two receptors. (b) 
Using the complemented receptors as a donor, BRET1 to an acceptor Venus which is fused to 
Gα subunit can be measured by taking a ratio between the luminescence (shown as blue light) 
and fluorescence (read at 525nm, shown as yellow light). Agonist-stimulated BRET1 change, 
indicative of G protein-coupling, can be plotted against increasing concentrations of ligands for 






is a luminescence emitting reporter of calcium (after binding of both calcium and its substrate 
coelenterazine). With the use of recombinant aequorins, this technique allows targeting to distinct 
subcellular compartments (e.g. mitochondria, ER, or surface membrane). Nonetheless, fluorescent 
dye was chosen to avoid the need for transfection and thus to allow similar approaches in 
heterologous cells, primary culture, and ultimately brain slices.  
The indicator dye molecule consists of two parts: the calcium-binding part and fluorescent 
part. The molecule changes its shape when calcium binds to it, thereby altering the conformation 
of the fluorescent part of the molecule. The calcium-binding parts have been derived from the 
calcium chelators EGTA and BAPTA, both of which bind to calcium with high affinity and one-to-
one stoichiometry. There is a palette full of variations for the fluorescent tails162. There are two 
general categories of indicator dyes – non-ratiometric and ratiometric indicators. Non-ratiometric 
indicators generally have a high signal to noise ratio. Ratiometric indicators have the advantage 
that there is a built-in control for loading as the calcium-free and calcium-bound form each has a 
distinct peak at different wavelengths. Since an overlap of spectral range between the indicator 
dye and fluorescent proteins expressed in the cultured cells was an initial concern, a non-
ratiometric indicator was chosen. However, the results obtained with non-ratiometric indicators 
have to be carefully assessed and possible errors have to be controlled for since there are known 
hurdles. One major hurdle is to control for the equal loading from one experiment to the other. 
The other concern is bleaching of the indicator. The latter can be successfully avoided by using a 
two-photon laser microscope. To increase the indicator loading efficiency, lipophilic groups (e.g. 
acetoxymethyl (AM) groups) are added to the charged indicator molecule. The indicator complex 





the cytosol, cytoplasmic esterases cleave off the lipophilic groups. The free indicator molecule 
then binds and detects calcium while confined in the cytosol. The lipophilic indicator complex is 
typically dissolved in dimethylsulfoxide (DMSO) and the detergent Pluronic to disperse the 
indicator molecules and facilitate cell loading. Cells are typically loaded with the indicator by bath 
application with a final indicator concentration of 1–10 µM and loaded for 30–60 min to ensure 
that all lipophilic groups have been cleaved off by cytoplasmic esterases. Finally, the dissociation 
constant is an important consideration in picking the appropriate right indicator. The following 
equation determines the range of detectable calcium concentration. 




where Fmin and Fmax are fluorescence intensity at virtually zero and saturating [Ca2+]in respectively. 
Kd is the dissociation constant. In a plot of F against [Ca2+]in, Kd is the [Ca2+] where F is half-way 
between Fmin and Fmax and this is where the indicator displays its largest sensitivity163. The rule of 
thumb is if the Kd is 10-7-10-6, then it can cover the physiological range of calcium changes with an 
optimal signal. The indicator used in our studies is Asante Calcium Red (ACR, Teflabs) and it has Kd 
= 4x10-7. ACR was chosen because of its emission spectrum peak (650 nm) to make it possible to 
perform calcium imaging in striatal cultures from mice expressing eGFP  eGFP (emission peak at 
510 nm) and tdTomato (emission peak at 580 nm) in D2R- or D1R-expressing cells, respectively. 
Thus the calcium signal (650 nm) should not overlap with the reporters allowing tracking of the 
signal change in either D1R- or D2R-expressing cells specifically. It is important to note that these 
values are taken from 1-photon spectra and may not be reflected in the 2-photon properties of 





Materials and methods 
List of drugs with intended targets (alphabetical) 
Name Target Agonist Antagonist Vendor 
5-HT 5HT2AR X  Sigma-Aldrich 
Acetylcholine mAChR (M3R) X  Sigma-Aldrich 
Adenosine A2AR X  Sigma-Aldrich 
ATP P2YRs X  Sigma-Aldrich 
Bicuculline GABAAR  X Tocris 
CGP55845 GABABR  X Tocris 
CGS21680 A2AR X  Tocris 
Cholera toxin Gαs subunit  X* Sigma-Aldrich 
CNQX AMPAR  X Tocris 
DA D1R, D2R, D5R X  Sigma-Aldrich 
Dihydrexidine D1R, D2R  X Tocris 
Forskolin AC X  Sigma-Aldrich 
Gallein Gβγ subunit  X Tocris 
Isoproterenol β2AR X  RTI 
Ketanserin 5HT2AR  X Sigma-Aldrich 
KT5720 PKA  X Tocris 
M119 Gβγ subunit  X NCI 
M119B Gβγ subunit  X NCI 
M158 Gβγ subunit  X NCI 
M201 Gβγ subunit  X NCI 
MK801 NMDAR  X Tocris 
NPA D1R, D2R X  Sigma-Aldrich 
Pertussis toxin Gαi subunit  X Sigma-Aldrich 
Pirenzepine M1R, M3R  X Sigma-Aldrich 
Quinpirole D2R X  Tocris 
SCH23390 D1R  X Sigma-Aldrich 
SCH442416 A2AR  X Tocris 
SKF38393 D1R X  Sigma-Aldrich 
SKF81297 D1R, D2R X  Tocris 
SKF83822 D1R X  Tocris 
SKF83959 D1R, D2R, D5R X  Tocris 
Sulpiride D2R  X RTI 
Tetrodotoxin Na+-channel  X Abcam 
U73122 PLC  X Tocris 





Molecular biology and HEK cell culture 
The cDNAs for human D1R, 3xHA-A2AR, M1R, Gαs short, Gαolf, were obtained from 
www.cdna.org. D1R and M1R were tagged with signal peptide (SP)164 followed by a Myc epitope 
tag (SM hereafter) using standard molecular biology procedures. The cDNAs encoding full length 
Renilla Luciferase 8 (RLuc8) or fragments for the L1 (a.a. 1-229) or L2 (a.a. 230-311) were fused in 
frame to the C-terminus of SM-D1R, 3xHA-A2AR, SM-A2AR, or M1R in the pcDNA3.1 vector. The 
human D2sR sensors were already reported87 and D2lgR constructs were made accordingly. These 
D2 constructs were N-terminally fused to SP followed by a flag epitope (SF hereafter). 
The following human G protein constructs were used: untagged Gαi1, Gαs short, Gαs long, 
Gαolf, Gαi1-mVenus with mVenus inserted at position 60, 91, or 122, Gαs short-mVenus with 
mVenus inserted at position 7, 67, 71165, 99, 131, 154, 175, 305, or 338, Gαolf-mVenus with 
mVenus inserted at position 8, 69, 72, 100, 132, 155, 176, 306, Gαq-mVenus with mVenus inserted 
at position 97 (see sequence alignment in Chaper 3). Gαi1-RLuc (humanized Renilla Luciferase, 
used only in Chapter 2-1) or RLuc8 was inserted at position 91, Gαs long-RLuc with RLuc inserted 
at position 113 (used only in Chapter 2-1), Gαs short-RLuc8 with RLuc8 inserted at position 7, 67, 
71, 99, 131, 154, 175, 305, 338, Gαolf-RLuc8 with RLuc8 inserted at position 8, 69, 72, 100, 132, 
155, 176, 306, Gαq-RLuc8 with RLuc8 inserted at position 97, Gα11-RLuc8 with RLuc8 inserted at 
position 97 (see sequence alignment in Chaper 3), untagged Gβ1, Gβ1 fused with V2 (C-terminal 
split of mVenus, aa 156-240) at its N-terminus, untagged Gγ2, Gγ2 fused with V1 (N-terminal split 
of mVenus, aa 1-155) at its N-terminus, Gγ2 fused to full-length mVenus at its N-terminus. All the 
constructs were confirmed by sequencing analysis. Several constructs were kindly shared by Drs. 





293T cells using polyethylenimine (PEI) (Polysciences Inc) in a 1 to 3 ratio in 10 cm dishes. Cells 
were maintained in culture with DMEM supplemented with 10% FBS. The transfected amount and 
ratio among the receptor-L1, receptor-L2, Gα, Gβ1, Gγ2 was optimized by testing various ratios of 
plasmids encoding the different sensors. Experiments were performed ~48 hours post-
transfection. For experiments involving the A2AR, 0.2 U/ml adenosine deaminase (Roche) was 
added overnight to lower endogenous adenosine that could interfere with ligand binding. 
Stable cell lines were generated as described2. D2s stable line refers to SF-D2s expressing 
cells, D1 stable line refers to inducible expression line of 3xHA-D1 in Flp-In T-REx 293 cells 
(Invitrogen), and D1 D2s double stable line also refers to Flp-In T-REx 293 cells (Invitrogen) with 
inducible 3xHA-D1 expression but also stably expressing D2s. The receptors under inducible 
promoters were incubated in 1 µg/ml tetracycline containing medium overnight to induce 
expression (shown in Chapter 4). 
 
BRET1, BRET2, and luminescence reading 
BRET1 uses a yellow fluorescent protein variant (mVenus) as an acceptor for energy 
transfer from luciferase and was measured as described87. BRET2 uses a green fluorescent protein 
variant (GFP10) as an acceptor for energy transfer from luciferase and was performed as 
described166. Briefly, cells were harvested, washed and resuspended in PBS. Approximately 
200,000 cells/well were distributed in 96-well plates and 5 μM coelenterazine H (substrate for 
luciferase in BRET1) or 5 μM deep blue c (substrate for RLuciferase8 in BRET2) was added to each 





antagonist was added 15 min before the addition of agonist. The fluorescence (excitation at 500 
nm and emission at 540 nm for 1 sec recording in BRET1 or excitation at 410 nm and emission at 
510 nm for 1s recording in BRET2) and luminescence (no filters, 1 sec recording) were quantified 
2.5 min after a ligand was added (Polarstar, Pherastar, and Pherastar FS BMG). In parallel, the 
BRET signal from the same batch of cells was determined by quantifying and calculating the ratio 
of the light emitted by mVenus (510–540 nm) over that emitted by RLuc8 or RLuc (485 nm) for 
BRET1 and the ratio of the light emitted by GFP10 (515 nm) over that emitted by RLuc8 (370-450 
nm) for BRET2. The net BRET values were obtained by subtracting the background determined in 
cells expressing RLuc8 or RLuc alone. Results are expressed as the BRET change produced by the 
corresponding drug. As shown in the cartoons, bimolecular complementation of donor was 
incorporated into the BRET assay. RET took place between complemented luciferase complex and 
Gα-mVenus. Data and statistical analysis were performed with Prism 5.01 (GraphPad Software). 
Similarly tranfected and distributed cells were used for luminescence reading and it was measured 
without a filter at a gain setting of 3000 in Pheraster. 
 
Fluorescence activated cell sorting (FACS) 
FACS was performed to determine cell surface expression of each receptor construct, as 
described167 with a C6 Flow Cytometer (Accuri). Briefly, a fraction of the same cells used for 
luminescence complementation was harvested and incubated with anti-Flag M1 (Sigma), anti-Myc 
(Hybridoma Facility, Mount Sinai, New York), or anti-HA (Santa Cruz), washed and incubated with 







 All procedures were carried out in accordance with the National Institutes of Health (NIH) 
Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal 
Care and Use Committee at Columbia University and the New York State Psychiatric Institute. 
Wild-type (WT), double transgenic expressing BAC-reporters (drd1a-Tomato/drd2-EGFP) male 
congenic C57Bl/6j mice (postnatal ages 90–150 days) were used for indirect fluorescence 
immunostaining and PLA. WT mice postnatal day 0 were used for striatal primary culture. All 
animals were group-housed in a standard animal care facility with a 12-h light/dark cycle, in which 
they had free access to food and water. 
 
Indirect fluorescence immunostaning 
Brain slice samples (30 µm) were prepared using fixed tissue as described146. Sections 
were rinsed four times in TBS (0.1 M Tris, pH.7.4, and 0.9% w/v NaCl), and incubated with blocking 
solution (10% FBS and 0.2% Triton X-100 in TBS) for 2 h at room temperature. The slices were 
incubated with the primary antibodies overnight at 4°C. After four rinses (30 min each) in TBS 
(0.2% Triton X-100), sections were incubated for 2 h at room temperature with the appropriate 
secondary antibodies conjugated with Alexa dyes (Invitrogen, Carlsbad, CA, USA), then washed six 
more times (30 min each) with TBS (0.2% Triton X-100), and mounted on slides with Fluorsave 





FV1000 confocal laser scanning microscope (Olympus, Center Valley, PA, USA) with a 60x 
objective. 
 
Two-week-old neuronal culture was rinsed with PBS once then fixed with 4% 
paraformaldehyde in PBS for 10 min. Fixed cultures were washed three times with PBS, 
permeabilized with 0.1% Triton-100 in PBS for 10 min then blocked with 5% BSA in PBS for 1 hr at 
room temperature. Without rinsing, the blocked cultures were incubated with mouse anti-D1R 
(Sigma) and rabbit anti-D2R (custom-made) (1:300 dilution in PBS containing 5% BSA) overnight at 
4 °C. The cultures were washed five times with PBS then incubated with Alexa 488-labelled anti-
mouse IgG (Invitrogen) and Alexa 546-labelled anti-rabbit IgG (Invitrogen) (1:1000 dilution in PBS 
containing 5% BSA) for 1 hr at room temperature. The cultures were rinsed three times with PBS 
and the images were taken with an Axio Imager Z1 fluorescence microscope (Zeiss) 
 
PLA using Duolink 
Detailed protocol using the Duolink kit was described previously146. Briefly, PLA was 
performed in a similar manner as standard immunohistochemistry until the secondary antibody 
incubation step. Samples were incubated in PLA secondary probes, followed by hybridization and 
ligation of the circle-forming DNA. DNA polymerase was added to amplify the circular DNA and 
subsequently Atto590-labeled oligonucleotide detection probes were added for visualizing the 





visualized on a Fluoview FV1000 confocal laser scanning microscope (Olympus, Center Valley, PA, 
USA) with a 60x objective. 
 
Antibodies 
For immunostaining in BAC transgenic mice, anti-GFP (Abcam) and ati-DsRed (Clontech) 
antibodies were used at 1/500 dilution. For immunostaining and PLA, anti-D1R antibody (Sigma) 
was used at 1/500 dilution and anti-D2R antibody (in house146) was used at 1/500-1/200 dilution. 
For immunostaining, all the fluorescent secondary antibodies were used at a concentration 
1/1000. For FACS analysis, 1/200 dilution was used for all anti-flag, anti-HA, anti-Myc antibodies, 
and subsequent fluorescent secondary antibodies. 
 
Striatal neuron culture 
The striatum was dissected from postnatal day 1 mouse in chilled PBS. The tissue was 
digested with papain for 15 min and dissociated using a fire-polished Pasteur pipette. Dissociated 
neurons were suspended in glial-conditioned Neurobasal A medium (Invitrogen) supplemented 
with B27 (Invitrogen), 0.25 µM glutamine (Invitrogen), 10 ng/mL brain-derived neurotrophic factor 
(BDNF, Sigma) and 10 ng/mL glial cell line-derived neurotrophic factor (GDNF, Sigma). Neurons 
were plated at a density of 80000 per well on top of the 2-week-old glia culture growing on the 12 
mm round glass coverslips in 24-well plate. 50 µg/mL uridine (Sigma) and 20 µg 5-







Flipr5 calcium assay using Flexstation3 
Experiments were done according to the protocol provided with Flipr5 kit (Molecular 
devices). Briefly, cells were resuspended in HBSS buffer containing 20 mM HEPES and 2.5 mM 
probenecid and distributed in 40 µl volume in 96 well plates (500,000cells/well). Fifty µl Flipr5 dye 
(Molecular devices) was added to each well and incubated in 37C 5% CO2 for 1 hour. 10x 
concentrated ligand plates were prepared in HBSS with 20 mM HEPES. During the reading with 
Flexstation3 (Molecular devices), 10 µl ligand was injected to the well at the indicated times. 
Intracellular calcium levels were measured every 2 sec over the course of ~220 sec. Data was 
analyzed by Softmax Pro 5.4 (Molecular devices). 
 
Asante calcium red calcium assay using multiphoton microscope 
Asante calcium red (ACR, Teflab) was diluted first in Pluronic F127 (Invitrogen), then in 
HBSS buffer containing calcium and magnesium (Gibco) supplemented with 20 mM HEPES and 5 
mM glucose to a final concentration of 5 µM. Primary neurons grown on a coverslip was incubated 
in the above dye mix for 1-2 hours in the 37C 5% CO2 incubator, washed, and transferred to a 
temperature-regulated perfusion chamber (37C) on the microscope stage. To avoid neuronal firing 
due to cell-cell communication, HBSS buffer with 20 mM HEPES and 5 mM glucose containing 
antagonists (10 µM CNQX for AMPA/kinate receptors, 2 µM MK801 for NMDA receptor, 20 µM 
bicuculline for GABAA receptor, 2 µM CGP55845 for GABAB receptor, 10 µM tetrodotoxin for Na+-





Throughout the experiments, this antagonist mix was used for perfusion (also temperature 
regulated, 37C) and drug incubation. Increases in intracellular free calcium were measured by 
multiphoton microscopy of the indicator ACR. The fluorophore was excited at 820 nm (Chameleon 
Vision II Ti:Sapphire laser, Coherent) and emission was collected using a 607/50 nm bandpass 
filter. A Prairie Ultima II system built on an Axio Examiner microscope body (Zeiss) with a 20x 1.0 
NA objective and Prairie View software v4.3.1.20 (Prairie Technologies), was used for controlling 





Chapter 2 : Dimer pharmacology in putative dopamine D1R-D2R heteromers 
 
Background and significance (Chapter 2) 
Since the discovery of rhodopsin dimerization in native optic disc membrane, interactions 
between many different Family A receptors have been reported but there is a lack of evidence for 
an identifiable dimer unit as the basis of a specific signaling event. As a paradigm, receptor dimer 
pharmacology has a potential to be of importance. For instance, it may increase the specificity of 
targeted effects and thereby reduce activation of other pathways that may lead to side effects. 
However, a big hurdle to investigating it is that we do not have a way to directly measure dimer 
specific signaling events. Particularly, for DA receptors there have been numerous reports of 
homo-dimerization as well as of hetero-dimerization with various other receptors, indirectly 
implicating their functional significance. But the observation for functional dimer unit is not 
definitive, and much of the literature could be the result of over-interpretation using tools that are 
incapable of yielding definitive conclusions. In Chapter 2 of my thesis work, we devised an assay 
system that allows pharmacological studies of clearly defined dimers. This let us ask questions 
regarding G protein activation differences between two defined pairs of dimers such as homo-D2 
dimer and hetero-D2-D1 dimer. Taking this receptor pharmacology approach further, functional 
selectivity of ligands in several G protein activation as well as arrestin3 recruitment paradigms was 







Results (Chapter 2) 
 
Part 1: D1R-D2R heterodimer-specific functional selectivity 
Measuring receptor activation by receptor-G protein BRET 
We first studied dopamine D1 and D2 receptor (D1R and D2R) conformational changes in a 
BRET-based receptor-G protein assay upon stimulation with the endogenous agonist dopamine 
(Figure 2-1a,c). The BRET1 assay requires an energy donor, Renilla Luciferase 8168 (RLuc8), fused to 
the C-terminus of the receptor of interest and an acceptor, mVenus169, inserted into the Gα 
subunit at the same position where luciferase was introduced previously170. These sensors have 
been previously characterized and do not significantly alter the function87, 166, 170 of the wild type 
(wt) proteins. This technology has been used to monitor conformational changes at the level of 
the GPCR-G protein interaction for other receptors166. Consistent with the known coupling of D1R 
to Gαs, dopamine caused a significant BRET change in cells expressing D1R-RLuc8 with Gαs-
mVenus but not with Gαi-mVenus (Figure 2-1a). This G protein specificity was also observed with 
another D1R agonist (Figure 2-1b). 
Similarly, consistent with the known coupling of D2R to Gαi/o, in cells coexpressing D2R-
RLuc8 with Gαi1-mVenus we detected a significant dopamine induced BRET change, whereas no 
change in BRET was detected with Gαs mVenus (Figure 2-1c). Other D2R agonists also led to 
enhancement of the D2R-G protein BRET signal only with Gαi-mVenus and not Gαs-mVenus 
(Figure 2-1d). We evaluated three different mVenus insertion positions in Gαi, and we detected 





experiments we used the position 91 Gαi-mVenus fusion (Table 2-2). Changes in BRET observed 
with receptor-G protein based biosensors are indicative of conformational change and not 
necessarily of G protein activation. Importantly, when the sensor is inserted at position 91 of the 
Gαi subunit, the G protein conformational changes have been shown to correlate closely with G 
protein activation170. In order to confirm that the conformational change induced by dopamine 
also parallels G protein activation, we performed a series of experiments using a G protein 
biosensor in a configuration that monitors conformational changes at the level of the G protein 
heterotrimer itself. We expressed a non-tagged receptor (D1R or D2R) together with a Gα-RLuc, 
mVenus-Gγ2 and untagged Gβ1 and we quantified dopamine-induced BRET (Figure 2-1e,g, Table 
2-2). As with the receptor-Gα based biosensor, we only detected BRET changes when the cognate 
Gα protein was coexpressed along with D1R or D2R (Figure 2-1e,g). Agonist-induced BRET changes 
were inhibited by specific antagonists (Figure 2-1f,h), consistent with the biosensor reporting on 
receptor activation 
Thus, as described previously for a BRET2 assay with adrenergic receptors and related Gα 
biosensors with luciferase or GFP10 inserted at the equivalent of position 91170, we were able to 
use agonist-induced BRET1 changes to monitor conformational changes that are associated with 
the activation process. Maximal agonist-induced BRET changes were observed upon coexpression 






Figure 2-1 G protein BRET biosensors measure conformational changes associated with 
dopamine receptor activation. 
HEK 293T cells were transiently transfected D1R (a,b) or D2R (c,d) full length RLuc8 C-terminal 
fusions with Gαs-mVenus (red symbols and curves) or Gαi-mVenus (black symbols and curves) 
together with unlabeled β1 and γ2; or the unfused receptor D1R (e,f) or D2R (g,h) together with 
Gαs-RLuc (red symbols and curves) or Gαi-RLuc (black symbols and curves) and mVenus-γ2 and 
unfused β1. BRET1 was performed as described in Materials and Methods and results were fit by 
non-linear regression to a sigmoidal dose-response relationship against the dopamine 





represent S.E.M.) are shown, and summary data are presented in Tables 2-1, 2-2. The cartoons 
indicate the constructs expressed: D1R in red and D2R in black with the full length RLuc8 (blue) at 
the C-terminus and the indicated Gα sensor (red for Gαs or black for Gαi with the β1 (in green) and 
γ2 (in light blue) subunits; the dotted arrow represents the energy. Open square symbols 
represent antagonist treatment. 
 
We obtained similar results with a biosensor that monitored receptor interaction with 
Gβγ. Here the energy acceptor was a Gβγ-mVenus biosensor, formed by complementation of split 
mVenus fusion constructs of Gβ1 and Gγ2171, 172 (Table 2-2), which allows tight control of Gβγ 
isoforms. Although these biosensors proved robust when coexpressed with receptor fused to 
RLuc8 and unlabeled Gα, a small component of the signal resulted from endogenous Gα (Table 2-
2), and therefore this orientation of the assay does not give the same precision when studying 
conformational changes in a defined Gα subunit. Nonetheless, this novel biosensor is of great 
potential utility as it allows monitoring conformational changes in defined combinations of Gβ and 
Gγ subunits, an aspect of GPCR signaling that is not well understood. 
 
Expression of D1R alters NPA-induced D2R-G protein BRET 
Next we evaluated the impact of receptor coexpression on the agonist induced BRET 
change. While coexpression of untagged D2R did not alter D1Rdependent Gαs conformational 
change (Figure 2-2a), the presence of D1R modified D2R-mediated agonist-induced BRET changes 





D1R, we observed a significant gain of potency for R(−) -propylnorapomorphine (NPA) (p=0.0001, 
Figure 2-2b, Table 2-1), without any change in coupling specificity (Figure 2-2c). These data are 
compatible with the possibility that D1R-D2R heteromerization may be responsible for at least 
some of the functional selectivity manifested in the ability of different D2R drugs to promote 
different conformational rearrangements. Although we cannot completely rule out signaling 
integration resulting from crosstalk of parallel effector pathways, our readout is upstream at the 
level of the receptor-G protein interaction and not downstream effectors where integration might 






Controlling the protomers in a signaling unit 
To dissect functional selectivity of D2R drugs at the dimer level, we sought to devise a 
method that would allow dissection of G protein conformational changes by a defined receptor 
dimer using receptor sensors recently validated for D2R87 that exploit complementation of split 
luciferase as a reporter of molecular proximity173. In these constructs the C-terminus of the 
receptor is fused to an N-terminal fragment (L1) or C-terminal fragment (L2) of RLuc8. We also 
constructed the equivalent D1R fusion constructs. No differences between D2R-D2R and D1R-D2R 
were observed when molecular proximity was evaluated by luciferase complementation (Figure 2-
3c) or by BRET titration experiments (Figure 2-3a), suggesting a similar propensity for homo- and 
heteromerization. Similarly, none of the ligands tested altered the propensity for interaction based 
on the results of D1R-D2R BRET titration experiments (Figure 2-3b). Furthermore, none of the 
drugs targeting one or both receptors altered RLuc8 complementation of the split D1R-D2R or 
D2R-D2R constructs (Figure 2-3d-e). 
Figure 2-2 D1R coexpression enhances NPA potency at D2R. 
HEK 293T cells were transiently transfected wild type human D1R (a) or D2R (b) full length 
RLuc8 C-terminal fusions alone or in combination with unfused D2R (a) or D1R (b) 
respectively; together with Gαs-mVenus (a) or Gαi-mVenus (b) and unfused β1 and γ2 G 
protein subunits. In (c), D2R-RLuc8 with unfused D1R together with Gαs-mVenus with 
unfused β1 and γ2 G protein subunits were transiently transfected. Summary data are 







Figure 2-3 D2R interacts similarly with itself and with D1R and ligand binding to D2R and/or 
to D1R does not alter BRET interaction and luminescence complementation. 
(a) BRET50 values between D1R and D2R are summarized. (b) BRET50 between D1R-Rluc8 and 
D2R-mVenus in the presence of various drugs are summarized. (c) In D2R-L1 and D2R-L2 (open 
symbols and dashed) or D2R-L1 and D1R-L2 (closed symbols and continuous line), 
luminescence was recorded in the absence (c) or in the presence (d) of several selective and 6 
nonselective agonists and selective inverse agonists. Background was determined with cells 
expressing only one of the receptor probes and the signal to background ratio was plotted 
against the FACS ratio. For the FACS ratio, cells transfected in parallel were labeled with 
primary and secondary antibodies as described in the Material and Methods. Relative staining 
for each receptor was determined independently in the same cells with the same secondary 
anti-mouse antibody to determine the FACS ratio. Representative results from at least 2-3 






Receptor-G protein BRET experiments similar to those described above (Figure 2-1) were 
performed in cells that coexpressed D1R-L1 and D1R-L2 or D2R-L1 and D2R-L2 with the Gαs or Gαi 
mVenus acceptors. Dopamine enhanced the BRET signal in cells that coexpressed D1R-L1, D1R-L2 
and Gαs-mVenus (Figure 2-4b) and D2R-L1, D2R-L2 and Gαi-mVenus (Figure 2-4f), but not when 
the D1R-splits were coexpressed with Gαi-mVenus (Figure 2-4b) or the D2R-splits were expressed 
with Gαs-mVenus (Figure 2-4f), consistent with the expected G protein coupling specificity. G 
protein specificity also was observed with D1R (Figure 2-4c-d) or D2R agonists (Figure 2-4g-h). No 
significant differences in the potency of dopamine-induced BRET changes were observed between 
the full length receptor-luciferase fusions and the split luciferase receptor constructs (Table 2-1). 
This indicates not only that the splits express and function normally, but also that the orientation 
of the complemented donor is similar and has not introduced an observable alteration of the 
receptor-G protein interface. As for the full length RLuc8 donor assays, Gαi with mVenus inserted 
at position 91 resulted in the best dynamic range and was used for all subsequent experiments. 
Importantly, selective drugs did not trigger any BRET change if the target receptor was not 
expressed (quinpirole, Figure 2-5a green). D1R agonists caused concentration-dependent 
conformational changes in the D1R homomer indicative of Gαs activation that are in agreement 
with the relative potencies and efficacies reported previously using other assays174 (Figures 2-4a, 
2-5a, Table 2-1). The same was observed for D2R homomer activation of Gαi, which identified NPA 
as the most potent agonist studied (Figure 2-4e-h, Table 2-1). Comparable results were observed 






Figure 2-4 Characterization of homomeric receptors in G protein signaling complexes. 
HEK 293T cells coexpressing D1R-L1, D1R-L2 and Gαs-mVenus (red symbols and curves) or Gαi-
mVenus (black symbols) (a-d) or D2R-L1, D2RL2 and Gαi-mVenus (black symbols and curves) or 
Gαs-mVenus (red symbols) (e-h) were prepared as in Figure 2-1. In experiments in which 
antagonists (SCH23390, sulpiride) were used (b, f open symbols), the antagonists (1 μM) were 
preincubated for 15 mins at RT before the addition of the substrate and the tested agonist. 






As expected, selective antagonists dramatically decreased agonist potency at the cognate 
receptor. In cells coexpressing the D1R splits and Gαs-mVenus, the D1R antagonist SCH23390 
decreased the potency of dopamine and SKF83822 for activating Gαs (Figures 2-4b, 2-5b); and the 
D2R antagonist sulpiride decreased the potency of dopamine, NPA and quinpirole for activating 
Gαi (Figures 2-4f, 2-5c-d). In contrast, SCH23390 did not inhibit NPA- or quinpirole-induced BRET 
increase in D2R Gαi-mVenus expressing cells (Figure 2-5c-d). Notably the D2R-selective antagonist 
sulpiride has a fixed negative charge and at 1 μM is essentially membrane impermeant175. 
Therefore, the dramatic inhibition of the agonist-induced BRET change by this concentration of 
sulpiride in cells coexpressing the D2R splits and Gαi-mVenus, (Figures 2-4f, 2-5c-d), indicates that 





Targeting the D1R-D2R heteromeric signaling unit 
This approach allows targeting of specific protomers through luciferase complementation 
and thus analysis of signaling of defined heteromers without a contribution from homomeric 
complexes (Figure 2-7). Thus, by coexpressing D1R-L1 and D2R-L2 (or D2R-L1 and D1R-L2), the only 
luminescence signal will result from complementation of D1R and D2R and any homomeric species 
will be silent at the level of the BRET readout. We first studied the Gαs pathway by coexpressing 
both D2R-L1 and D1R-L2 with Gαs-mVenus. Selective D1R stimulation resulted in a concentration-
dependent BRET increase with agonist potencies similar to those observed in the D1R homomers 
(Figures 2-5e, 2-6a-d, Tables 2-1, 2-2). The D2R-specific agonist quinpirole did not alter the Gαs-
mVenus BRET signal (quinpirole, Figure 2-5e green). Furthermore, as expected, the selective D1R 
inhibitor SCH23390 competed with the D1R-selective compounds, whereas the D2R-selective 
antagonist sulpiride did not inhibit the D1R-mediated Gαs response (Figure 2-6a-d). Selective 
antagonism by SCH23390 was also seen for DAR100 (Figure 2-5f). Swapping the orientation of the 
splits led to the same results (Table 2-2). This set of experiments demonstrates that, agonist 
Figure 2-5 Characterization of Gα-based biosensors for D1R-D1R and D2R-D2R homomers and 
D1R-D2R homomer. 
(a-b) Selective agonist induced BRET was tested for Gs sensor with D1R-L1 D1R-L2 in the 
presence of antagonist (b). (c-d) G protein specificity and 1 μM antagonist selectivity were 
tested with quinpirole (c) and NPA (d). (e-f) or D2R-L1, D1R-L2 together with Gαs-mVenus (e-h) 
Selective agonist induced BRET was tested for Gs sensor with D2R-L1 D1R-L2 in the presence of 






binding to the D1R protomer in a D1R-D2R complex is sufficient to trigger a conformational change 
between the heteromer and Gαs consistent with activation. This establishes that one agonist is 
sufficient to activate a receptor heteromer. Moreover, since our approach monitors the direct 
physical interaction between the receptor heteromer and Gα protein, downstream signaling 






Functional selectivity of NPA at the D2R-D1R heteromer 
Next, we studied the Gαi pathway by coexpressing D2R-L1 and D1R-L2 with Gαi-mVenus. 
Again D2R agonists led to BRET increases similar to those observed in the D2R homomers (Figure 
Figure 2-6 Characterization of the heteromeric receptors in G protein signaling complexes. 
HEK 293T cells coexpressing D2R-L1, D1R-L2 and Gαs-mVenus (ad) or Gαi-mVenus (e-h) were 
prepared as described in Figure 1. In experiments in which antagonists were used (open 
symbols), the antagonists (1 μM) were preincubated for 15 mins at RT before the addition of 
the substrate and the tested agonist. Summary data are presented in Table 2-1. 
 
Figure 2-7 CODA-RET: a new tool to allow investigation of defined dimer population. 
On the right when two different receptors (black and red) are expressed, using a conventional 
assay ligand-stimulated signaling response cannot be traced back to a specific population of 
receptors (e.g. black-black or red-red homomers or black-red heteromers). Using CODA-RET, G 





2-6e-h, Table 1). Swapping the splits led to comparable results with the same potency for 
quinpirole (Table 2-2). As expected, agonist-induced BRET was inhibited by the D2R antagonist 
sulpiride (Figure 3e-h), but not by the D1R antagonist SCH23390 (Figure 2-6e-h). Thus, agonist 
binding to the D2R in the heteromer triggers a conformational change in the D1R-D2R-Gαi 
signaling complex. Interestingly, in agreement with the increased potency for the NPA induced 
BRET change in D2R-RLuc8 Gαi-mVenus in the presence of untagged D1R (Figure 2-2b, Table 2-1), 





(p<0.005, Figure 2-8b, Table 2-1), whereas the potencies of quinpirole and dopamine were the 
same in the heteromer and homomer (Figure 2-8b). In contrast, when we studied NPA’s effects on 
Gαs, no difference was detected between D1R homo- or heteromers (Figure 2-8a, Tables 2-1, 2-2). 
These results provide evidence for a novel molecular mechanism for functional selectivity, by 
which a drug has different potencies when targeting homo- or heteromeric complexes. 
On the right where two different receptors (black and red) are expressed, with 
conventional assay approaches ligand-stimulated signaling response cannot be traced back to 
which populations of receptors (e.g. black-black or red-red homodimers). Now, because of the 
CODA-RET, G protein coupling only in the black-red heterodimer population can be specifically 
studied. 
 
Figure 2-8 CODA-RET reveals functional selectivity of NPA at the D2R-D1R heteromer and it is 
observed at functional levels. 
HEK 293T cells coexpressing D1R-L1 and D1R-L2 or D2R-L1 and D1R-L2 together with Gαs-
mVenus (a) or D2R-L1 and D2R-L2 or D2R-L1 and D1R-L2 together with Gαi-mVenus (b) were 
prepared. Summary data are presented in Table 2-1. (c) Using a BRET based cAMP biosensor, 
EC50 was measured for NPA and quinpirole in cells expressing either D2R alone or D2R and 
D1R. To normalize changes in D2 expression that impacted the D2R-specific agonist quinpirole, 
the data are reported as the fold differences between the two drugs were calculated. It is 17 







Since NPA also binds and activates D1R, it is conceivable that NPA binding to the D1R 
protomer in the heteromer might help to trans-activate Gαi and thereby enhance NPA’s potency, 
but our results suggest otherwise. The NPA-induced BRET change with the D1R-D2R-Gαi sensor 
was competed by the D2R-inhibitor sulpiride but not by the D1R-inhibitor SCH23390 (Figure 2-6h), 
suggesting that NPA activates Gαi only by binding to the D2R and not to the D1R. In addition, 
whereas complementation of a mutant D2R that does not bind agonist176 (D2R-D114A-L1) with 
D1R produced a heteromer that signaled normally to Gαs, neither NPA, quinpirole, nor dopamine 
signaled to Gαi (Table 2-2), indicating the binding to the D2R protomer is essential for Gαi 
activation. 
Importantly, expression of excess unlabelled D1R did not alter the ability of the D2R-D2R 
splits to activate Gαi (Table 2-2) and failed to allow the D2R-D2R splits to activate Gαs (data not 
shown177). Similarly, expression of unlabeled D2R did not impact the ability of the D1R-D1R splits 
to activate Gαs (Table 2-2) and failed to produce activation of Gαi (data not shown177). These 
critical controls establish that the biosensors only read out on the activity of the receptor 





















Gi-mediated coupling enhancement also seen in potency shift of cAMP level 
To confirm further the NPA potency shift in the D1R-D2R heterodimer, we measured 
cAMP downstream of G protein activation. cAMP level is positively and negatively regulated by 
Gs/olf and Gi/o, respectively, via adenylate cyclase activation and inactivation. Therefore, an 
increase in Gi activation results in a decrease in cAMP production. To measure cAMP levels, we 
used a BRET-based cAMP biosensor assay that relies on a conformational change of CAMYEL 
(cAMP sensor YFP-Epac-RLuc)178 upon cAMP binding to Epac. Relative proximity of the N-
terminally tagged YFP and C-terminally tagged RLuciferase decreases as cAMP binds to Epac. 
Therefore, an increase in cAMP level is detected as a decrease in BRET ratio while a decrease in 
cAMP is seen as an increase. By cotransfecting CAMYEL, D2R expressing cells were compared to 
D1R-D2R coexpressing cells (Figure 2-8c). D2 agonist response curves were measured after 
preincubation of forskolin to elevate the basal cAMP level. Also SCH23390 was added to block D1-
mediated cAMP enhancement. To avoid misinterpretation due to different expression levels of 
transfected DNA constructs in D2R and D1R-D2R cells, the ratios of EC50 values for quinpirole, 
which was not impacted by coexpression of D1R in CODA-RET, and that of NPA, which was, were 
calculated. NPA was 17-fold more potent than quinpirole in D2R. In D1R-D2R coexpressing cells, 
however, the NPA was 107-fold more potent than quinpirole, demonstrating that the potency shift 
of NPA in D1R-D2R heterodimers (Figure 2-8b) is propagated to the level of effector inactivation. 
 





 The effect of heteromerization on arrestin3 recruitment to the receptor was examined 
next. As described in Chapter 1, arrestin is recruited to a ligand-activated receptor through GRK-
dependent phosphorylation of intracellular amino acids. This process is thought to lead to 
receptor internalization to endosomal vesicles and functional desensitization of the receptor. To 
detect arrestin3 recruitment, an arrestin3 biosensor was constructed previously by fusing mVenus 
to the N-terminus of human arrestin353. Using the CODA-RET, D2 ligand stimulated arrestin3 
recruitment was measured in complemented D2R-D2R homomers and compared with that in D1R-
D2R heteromers (Figure 2-9). HEK cells used here were stably transfected with GRK2 to enhance 
its expression and thus effective arrestin recruitment53. In all the experiments cells were 
pretreated with 1 µM SCH23390 to block D1R-mediated arrestin3 recruitment. There was no 
difference detected in EC50 value between the homomer and heteromer for either NPA or 
quinpirole. This indicates that the transduction in conformational change between ligand binding 






Ligand-specific functional selectivity 
As is evident by comparing three different signaling modalities (summarized in Figures 2-
10-2-12), the potency shift observed in effector-coupling between D2R-D2R and D1R-D2R was not 
generalized to all D2R agonists. NPA but not quinpirole showed an enhancement in potency for Gi-
coupling (Figure 2-11). This enhancement was not seen for Gs-coupling (Figure 2-10) or arrestin3 
recruitment (Figure 2-12). Amongst other D2R ligands, dihydrexidine and PPHT showed a similar 
potency enhancement in D1R-D2R heteromer Gi coupling as was seen with NPA (data not shown). 
Thorough analysis of docking and conformational selection of various ligands to a D2R and D2R 
heteromer model may ultimately lead to a correlation between ligand binding and G protein or 
arrestin coupling. 
Figure 2-9 Arrestin3 recruitment to homo- and heterodimers. 
EC50 values of drug-induced BRET between the D2R-D2R homodimer and arrestin3 or 
between D2R-D1R heterodimer and arrestin3 were determined by nonlinear regression 
fitting of the BRET curves. D2R-D1R heterodimer experiments were done in the presence of 
1μM SCH23390 to block the ligand effect through D1R. Using a BRET based cAMP biosensor, 
EC50 was calculated for NPA and quinpirole in either cells expressing D2R L1 and L2 or D2R L1 








Figure 2-11 For Gs interaction, there is no potency difference between D2R-D2R and D1R-D2R 
for DHX or NPA. 
 
Figure 2-10 For Gi interaction, potency of NPA, but not quinpirole is enhanced in the D1R-D2R 








Enhancement of NPA mediated Gs coupling in the presence of D2R antagonist 
 Antipsychotics bind primarily D2Rs to block Gi activation. This conformational stabilization 
can exert additional effects in the heteromer signaling unit. Thus, the effect of D2R antagonist on 
G protein coupling to the next protomer in the heterodimer was studied next. In the CODA-RET 
assay, treatment with sulpiride enhanced NPA activated Gs coupling efficacy in the heterodimer 
(Figure 2-13a). This was not observed with other D1R agonists [SKF81297 (Figure 2-6c), SKF38393 
(Figure 2-6d), including DA (data not shown)]. The efficacy enhancement with NPA was also seen 
in non-complemented D1R-D2R interaction (Figure 2-13b) ruling out a complementation artifact. 
We studied the downstream functional effect with the CAMYEL cAMP biosensor. Cells were 
treated with pertussis toxin (PTX) overnight to turn off the D2R-mediated Gi activation by NPA. 
Sulpiride showed a small but significant enhancement of NPA-induced cAMP production in the 
Figure 2-12 For arrestin3 recruitment, there is no potency difference between D2R-D2R and 





D1R/D2R coexpressing cells (Figure 2-13c). One of the possible mechanisms that could explain 
these results is that the conformational status of inverse agonist-bound D2R exerts an allosteric 
effect on the adjacent D1R that enables better transduction from ligand binding to Gs-coupling. 
This was previously shown in in the analysis of D2R homodimer activation where inactivation of 
one of the protomers leads to more efficacious G protein-mediated signaling from the second 
protomer (Figure 2-13d2). However, it must be noted that the effects in Figure 2-13a and 2-13b 
can be also interpreted as resulting from competition between Gs and Gi. That is, sulpiride-
induced block of the efficient NPA-induced Gi-coupling to the heteromeric complex could allow 
more efficient Gs coupling.  Although further investigation is needed to differentiate with certainty 
between these mechanisms, the inability of dopamine, which also activates Gi effectively at the 
heteromer, to reproduce this effect in the presence of sulpiride suggests that the effect is most 
likely due to allosteric interactions between protomers, reflecting another aspect of the unique 






Figure 2-13 D2R antagonist enhances NPA mediated Gs coupling to D2R-D1R heteromer. 
a) In the CODA-RET configuration, the presence of 1 μM sulpiride increases the efficacy of NPA-
mediated Gs-coupling. b) In non-complemented D2R D1R coexpression, 1 μM sulpiride also 
shows the efficacy enhancement of NPA-mediated Gs-coupling to D1R-Rluc. c) Using CAMYEL, 
cAMP level was measured in D2R D1R coexpressing cells treated with 100 ng/ml pertussis toxin 
overnight. One μM sulpiride increases the potency of NPA-mediated cAMP production. d) 
Antagonist enhancement of G protein coupling to the other protomer within the dimer has been 






Part 2: Lack of Gq-coupling to the DA receptors 
Investigation of Gq-coupling in D1R, D2sR, D2lgR, and D5R 
The most remarkable aspect of signaling reported to occur via the D1R-D2R heteromer is 
the purported coupling switch to Gq7, 9. As reviewed in Chapter 1, PLC activation has also been 
reported for other DA receptors33, 57, 68, 69. With BRET and CODA-RET approaches, we systematically 
investigated G protein coupling to different DA receptor species using BRET biosensor that read 
out on activation based on a conformational change between the α and γ subunits. The 
conformational change read-out by the sensors have been shown to reflect activation of the G 
proteins166, 170. In D1R, D2Rshort (D2sR), D2Rlong (D2lgR), and D5R single receptor populations 
(Figure 2-14), cognate G protein activation (i.e. D1R-Gs, D2sR-Gi1, D2lgR-Gi1, D5R-Gs) was 
detected by a change in BRET between the α and γ subunits after DA stimulation (Figure 2-14a-d, 
black solid) and this signal was inhibited, as expected, by the appropriate  antagonists (Figure 2-
14a-d, black dotted). Then, Gq activation was measured with either DA stimulation (Figure 2-14a-
d, orange) or SKF83959 stimulation (Figure 2-14a-d, blue). SKF83959 was used because it has been 
reported to be a PLC-linked agonist9, 67, 75, 77. Using the Gq biosensor we failed to detect a drug-
induced BRET change for DA or SKF83959 in all the dopamine receptors. To show the validity of 
the Gq biosensor179 in our hands, muscarinic receptor M1R, a Gq-coupled receptor, was expressed 
and stimulated by acetylcholine (ACh) (Figure 2-14e, black solid), which led to a consistent 






The PLC-linked Gq family of Gα proteins consists of Gq, G11, G14, and G15. In the striatum 
and nucleus accumbens, Gq and G11 are well expressed38. Thus, G11 activation in the DA 
receptors was investigated. Here BRET2 was used to detect the movement between G11 and γ 





(Figure 2-15a) or SKF83959 (Figure 2-15b) whereas ACh stimulation of M1R activates G11 and 
pirenzepine blocks it (Figure 2-15c). BRET between the receptor and Gq subunit was also tested 
with DA and SKF83959 treatment and did not yield any drug induced BRET (Table 2-3). Thus, each 
of the DA receptors was unable to activate either of the two major Gq-like proteins. 
Both D1R-D2R9 and D2R-D5R69 heteromers have been reported to couple to Gq protein. 
Thus, Gq activation was tested after coexpression of the two receptors (Figure 2-16). Unfused DA 
receptors were expressed with the Gq biosensor proteins. Neither stimulation by DA nor SKF83959 
led to Gq activation in D1R-D2sR (Figure 2-16a), D2sR-D5R (Figure 2-16b), D1R-D2lgR (Figure 2-
16c), or D2lgR-D5R (Figure 2-16d). Again, as a positive positive control, coexpression of M1R and 
different DA receptors was used (Figure 2-16a-d blue and e) and it did not show any apparent 
reduction in drug induced BRET by the M1R, indicating that the coexpression method did not 
impair the function of the Gq biosensor.  
Figure 2-14 Drug induced conformational change of Gq is not detected in D1/D5/D2s/D2lg. 
Conformational change of cognate G protein by DA was confirmed for a) D1R, b) D5R, c) D2sR, 
d)D2lgR (black solid) and it was blocked by their antagonists (black open). However, Gq 
activation was not observed in DA (orange) or SKF83959 (blue) addition for all of them. e) M1R 








Next, using the CODA-RET configuration, specific Gq-coupling to the defined heterodimer 
was tested to limit the signaling readout to that coming from the dimer (Figure 2-17).DA 
stimulation as well as costimulation by SKF83959 and quinpirole failed to trigger Gq-coupling in 
D1R-D2sR (Figure 2-17a), D2sR-D5R (Figure 2-17b), D1R-D2lgR (Figure 2-17c), and D2lgR-D5R 
(Figure 2-17d). In contrast, homodimer complementation of M1R (Figure 2-17e) or 5HT2AR (Figure 
Figure 2-15 Drug induced conformational change of G11 is also not detected in 
D1/D5/D2s/D2lg. 
Another Gq family G11 is also a PLC activator and prevalent G alpha protein in the striatum. 
D1/D5/D2s/D2lg did not show G11 conformational change after a) DA or b) SKF83959 addition 
(black = D1R, orange = D5R, blue = D2sR, red = D2lgR). c) M1R is shown as a positive control 






2-17f) showed efficient agonist stimulated Gq-coupling and antagonist blockade. This pair of 
positive controls showed that complemented luciferase does not interfere with Gq-coupling, at 
least to these two dimers. Other BRET results also point to the absence of Gq coupling or 
activation in any of the DA receptors or heterodimers tested (Table 2-3). There was no drug 
induced BRET between the monomer receptor and Gq (Table 2-3 top left). Despite its better 
sensitivity, BRET2 configuration did not pick up any drug induced signal from either single 
populations of DA receptors (Table 2-3 top right) or coexpressed populations (Table 2-3 bottom 
right). Taken together, we have been unable to detect Gq-like protein coupling to monomers or 
heteromers of DA receptors using multiple highly sensitive BRET sensors, making it unlikely that 
the PLC activation seen in the striatum or heterologous cells after DA receptor stimulation results 






Figure 2-16 Coexpression of D1R/D5R/D2sR/D2lgR in the same cell does not show drug 
induced activation of Gq. 
Coexpression of the two receptor species [a) D2sR-D1R, b) D2sR-D5R, c) D2lgR-D1R, d) D2lgR-
D5R] did not change the coupling status to Gq after drug stimulation (black = DA, orange = 
SKF83959). e) D1R/D5R/D2sR/D2lgR coexpressed with M1R showed that Gq coupling to M1R 







Figure 2-17 Defined receptor dimer pairs do not recruit Gq after drug stimulation. 
Using the CODA-RET approach, a receptor dimer pair is defined by luminescence 
complementation. All the dimer pairs shown [a) D2sR-D1R, b) D2sR-D5R, c) D2lgR-D1R, d) 
D2lgR-D5R] failed to reveal any conformational change between the receptor and Gq (black = 
DA, orange = SKF83959 + quinpirole). e) M1RL1 M1RL2 receptor pair as well as 5HT2ARL1 
5HT2ARL2 pair are shown as a positive control for Gq coupling (black solid = agonist, black 







Table 2-3 No drug-induced Gq activation was seen with any DA receptor combination. 
All the results with DA or SKF83959 stimulation in D1R/D5R/D2sR/D2lgR failed to show any drug 
induced BRET change in Gq-coupling in BRET1 (left table) and BRET2 (right table) configurations. 
‘+’ and ‘-’ indicate a positive and negative drug-induced BRET response. ‘0’ indicates no drug-
induced BRET. Color indicates the fused protein: blue (luciferase or split luciferase), orange 






Discussion (Chapter 2) 
 
We have developed a new methodology that allows the study of a signaling complex 
comprised of two defined GPCRs. This technology is based on quantifying the BRET between a 
receptor heteromer and a subunit of the heterotrimeric G protein or arrestin. Receptor-receptor 
interaction generates a complemented luminescence signal173 that serves as the energy donor of 
the assay. This creates tight control of the receptor species that participate in the energy transfer, 
allowing us to measure communication between a defined pair of receptor protomers and the G 
protein of choice, without contamination by homomeric signaling complexes or downstream 
crosstalk. Indeed, when studying heteromers with this methodology, homomers are “left in the 
dark,” since the formation of homomeric receptor complexes do not result in luminescence and 
therefore cannot contribute a signal in the BRET assay. We term this approach complemented 
donor acceptor resonance energy transfer (CODA-RET) to emphasize that it reports on interactions 
involving three or four entities. Importantly, this approach can also be used to explore the ability 
of defined receptor heteromers to recruit arrestin and can be extended to different interacting 
partners, as well as to FRET-based assays, by substituting split green fluorescent protein variants 
for the split luciferase constructs used here. 
In heterologous cells and in ex vivo systems, coexpression of two receptors has often been 
shown to lead to an alteration in pharmacology, trafficking, or generation of distinct downstream 
signals that differ from the properties of the individual receptors180. Although this is often taken as 
evidence of altered signaling by heteromers composed of the two different receptors, 





proximity is demonstrated between receptors with energy transfer assays, it is still not justified to 
conclude that signaling comes from the heteromer, as a fraction of the receptors may indeed 
interact, particularly in heterologous systems, but the functional entities may be the individual 
receptors or homomers interacting through downstream crosstalk. When two Class A receptors 
are coexpressed, homomeric and heteromeric species are likely to exist, and signaling could result 
from any combination of these receptor complexes181. Distinguishing between direct signaling 
from heteromers and indirect crosstalk downstream of homomers is of more than semantic 
importance. Given the opportunity for allosteric modulation between protomers in a heteromeric 
signaling unit2, 180, 182 novel drugs might be developed that would act differently at a heteromer 
than at a homomer, whereas with downstream crosstalk one would pursue a different 
pharmacological strategy to regulate signaling crosstalk. 
Certain compounds can differentially modulate various downstream signaling pathways 
upon binding to the same receptor183. This functional selectivity82 can manifest in different relative 
potencies of a drug at different downstream signaling or in the same molecule regulating different 
pathways in an opposite direction. Although this phenomenon is generally believed to result from 
different distributions of receptor conformations resulting from binding different ligands, our 
understanding of the underlying molecular mechanisms are quite limited. We have demonstrated 
here using CODA-RET that receptor heteromerization can result in functional selectivity, and we 
are able to establish for the first time that this functional selectivity results at the level of direct 
interaction of the heteromer with G protein and not as a result of downstream crosstalk. 
NPA, a high affinity D2R agonist caused an unexpected and previously undocumented 





compared to the D2R-D2R homomer. This is a clear example of functional selectivity because 
dopamine and quinpirole showed no significant shift in potency at the two complexes. The 
inability of the D1R antagonist SCH23390 to block NPA-induced Gαi BRET changes, and the loss of 
NPA-induced conformational changes upon mutation of the D2R binding site or in the presence of 
the specific D2R inverse agonist sulpiride, indicated that in the D1R-D2R heteromer the higher 
potency of NPA for Gαi only required its binding to the D2R and not to D1R. 
We have previously shown that complementation of receptor RLuc8 split constructs does 
not increase the interaction of the complemented receptors in the plasma membrane based on 
independent measurement of energy transfer between extracellular epitopes87. Furthermore, 
because the potency of NPA was enhanced similarly for the D1R-L1-D2R-L2 complemented 
complex and the D2R full-length RLuc8 fusion coexpressed with D1R, we conclude that the 
alteration in potency results not from the impact of complementation but rather from receptor-
receptor interaction. Thus, the ability to monitor G protein conformational changes selectively in a 
defined heteromer using CODA-RET should allow for more precise dissection of heteromeric 
signaling. A number of findings suggest that GPCR dimerization in the plasma membrane may be 
transient184-186. Even if GPCR interactions are transient, the substantial time the receptors spend 
together184, 187 is likely sufficient for the types of allosteric modulation between receptors that 
have been described2, 180, 182 and that can be revealed by CODA-RET. 
The molecular mechanism of the enhanced potency of NPA remains to be determined. 
The presence of the D1R in the heteromer somehow may exert an allosteric effect that modifies 
the binding site of the D2R and/or the mechanism by which agonist binding is propagated to G 





face of the D1R somehow contributes directly to the activation of Gαi mediated by the agonist-
bound D2R protomer in the heteromer, as has been inferred for the D2R homomer2. Nonetheless, 
by pharmacologically turning off the corresponding G protein coupling, we were able to show the 
potency enhancement in NPA at the cAMP level. This demonstrates that the potency shift of NPA 
in D1R-D2R heterodimers is propagated to the level of effector inactivation.  
In summary, our finding that the identity of the receptor partner in a GPCR heteromer can 
selectively alter the potency of agonist-induced signaling to G proteins indicates that receptor 
heteromerization is an important factor that must be considered in drug design and 
pharmacological analysis. Whether this is a general mechanism that can be exploited to develop 
new compounds selectively targeting D1R-D2R or other GPCR heteromers remains to be tested, 
but CODA-RET allows an approach to eliminating a contribution from homomeric signaling and 
analyzing the effect of drugs on defined GPCR heteromers. With the CODA-RET approach, we also 
concluded that there was no Gq-coupling to D1R, D2sR, D2lgR, D5R, in monomers as well as 
heterodimers, which ruled out Gq-coupling as the main activation mechanism for the reported DA 
receptor-mediated intracellular calcium release9, 33, 67-69. It is conceivable that somehow the 
complemented luciferase in the receptor interferes with Gq coupling, although we have shown 
that Gs, Gi and Go (data not shown) coupling to the complemented receptors is normal. Therefore 
we also pursued studies with Gq and Gq biosensors with DA receptors with completely unmodified 
cytoplasmic tails. Again, although we observed robust activation of the Gs, Gi, and Go sensors, we 
failed to see any evidence for Gq activation, despite the fact that the Gq sensor worked as 
expected for the M1R and 5HT2AR, both of which are known to couple Gq. Thus we conclude, that 





that many studies have inferred  Gq to be the intermediary mechanism for calcium mobilization 
without studying Gq but simply based on calcium measurements or IP3 production, both of which 
are consistent with PLC activation but do not necessitate Gq activation. Some reports, however, 
have shown GTPγS binding to Gq upon activation of various DA receptors9, 33, 67-69, 188. But with 









Chapter 3 : Towards better understanding of Gs coupling in A2AR and D1R 
 
Background and significance (Chapter 3) 
Improving our understanding of the structural and functional relationships of GPCRs and 
how this relates to G protein coupling status is a vital component of receptor pharmacology. . 
Adenosine A2A receptor (A2AR) and dopamine D1R are Gs/olf-coupling receptors expressed well 
in GABA-ergic medium spiny neurons (MSNs) that have been studied extensively as potential 
therapeutic targets in Parkinson’s disease and other neurological and psychiatric diseases. The 
purpose of this chapter is to better understand Gs activation in these receptors. 
Our understanding of conformational changes associated with receptor activation has 
been advanced profoundly by the recent crystal structure of agonist-bound β2 adrenergic receptor 
(β2AR) coupled to Gs189. By comparing it to the crystal structure of GTPγS-bound Gs190, large 
changes in G protein structure have been revealed. However, these static snapshots do not 
illustrate the dynamic nature of protein movement. 
Based on sequence alignment, structurally permissive positions were considered based on 
the folding of secondary structure and used for biosensor insertion sites. Using bioluminescence 
resonance energy transfer (BRET) with these constructs, we made observations on relative 
movements within the G protein and between the receptor and the G protein. We compared the 
data to the mechanisms proposed in recent studies189, 191. Next we investigated whether the 











Results (Chapter 3) 
 
Part 1: Differences in conformational change of Gs in D1R and A2AR 
Surveying the positions for sensor insertion 
The Gα subunit is largely conserved amongst its 16 subtypes in that it consists of three 
distinct domains (Figure 3-1): a long N-terminal helix, an α-helical domain, and a GTPase domain47. 
The N-terminal helix is palmitoylated and serves as a membrane associating arm. The α-helical 
domain is composed of six helices (termed αA-αF) and functions as a lid over the GTP-GDP binding 
pocket in the GTPase domain and affects the nucleotide exchange rate. The Ras domain (or 
GTPase domain) hydrolyzes GTP but also serves as a binding domain for Gβγ subunits, and is 
therefore structurally linked to the movement of the heterotrimer. The GTPase domain has three 
loops (switch I, II, and III) that undergo structural change upon GDP-GTP exchange. 
Originally, GFP was successfully inserted in the Gs protein at position #71165. This position 
was chosen because it is the splice site for short and long variants. Since the long variant has 15 
extra amino acids inserted at this site, it was considered safe to introduce extra amino acids in the 
short variant. This insertion site was also supported because it tolerated HA tag insertion192. To my 
knowledge, this position and #113 in Gs long177 are the only ones reported as insertion sites. In 
Gi1, there have been at least three different positions identified as tolerated166, 170. These are all 
located within loop domains of the α-helical domain. Taking an additional hint from the Gi1 site, 
all the loop regions in Gs short were taken into considerations except for the switch domains 





domains without defined secondary structure were chosen for the insertions. The positions 
chosen were #7, #67, #71, #99, #131, #154, #175, #305, #338, and #349 (Figures 3-1). 
Figure 3-1 Sensor protein was inserted at various loop positions outside of functional 
domains. 
Based on the crystal structure of GTPγS-bound Gs-β1-γ2 structure, loop structures were 






The Gs protein family consists of Gs and Golf. Golf protein is abundantly expressed in the 
striatum193, 194 and Golf shares 89% homology with Gs short. It has been reported that both A2AR 
and D1R signal through Golf protein36, 37, 194, 195. Therefore, positions chosen for Gs short were 
aligned with Golf, which revealed that the chosen residues were virtually identical (Figure 3-2). 
Subsequent molecular cloning led to insertion of the biosensors with either Rluc8 or mVenus 
flanked by four amino acid linkers at both ends at the ten different positions shown above. Thus a 
total of 32 constructs were generated. 
Two crystal structures of bovine Gs short are shown in Figure 3-3, with the insertion 
positions highlighted as blue balls. The crystal structures in Figure 3-3 are the GTPγS-bound 
Figure 3-2 DNA sequnce alignment between Gs short and Golf. 
Based on the high level of homology between Gs and Golf, Golf sensors were generated at the 






conformation of bovine Gs heterotrimer190 (Figure 3-3a)  and receptor-bound active conformation 
of bovine Gs heterotrimer189 (Figure 3-3b). Note that N-term α-helix is missing in GTPγS-bound 
structure (Figure 3-3a). In order to better visualize the conformational change within the Gs 
protein, the docked β2-adrenergic receptor was omitted from the structure (Figure 3-3b). The 
base of the receptor would have been situated at two o’clock position so that a part of the N-term 
helix (dark blue helix) and the top of α5 (red helix) made contact189. 
#7 is between the palmitoylation site and the beginning of the N-term alpha helix. #67 and 
#71 are in the loop connecting α1 to the first α-helix in the α-helical domain. #99, #131, #154, and 
#175 are in each of the loops within the α-helical domain. #306 is in the long stretch of a loop 
structure between αG and α4. #338 is in the loop facing the receptor docking side and #349 is at 
the bottom of α5, which associates with receptor at its opposite end (Figure 3-3 red helix). 
The first thing noticed about the difference between the GTPγS-bound and active 
structures is the dramatic movement of the α-helical domain (a complex of six helices starting 
from blue to light blue to green). This domain swings up at a >45° angle but there is no 
intramolecular movement within the α-helical domain189. It should be noted that the N-
term helix was not solved in the GTPγS-bound structure and is therefore missing (Figure 3-
3a). The superposition between the active Gs structure (Figure 3-3b) and the C-term of 
transducin in the metarhodopsin II structure (C-term of transducin is bound to the base of 
rhodopsin)196 revealed a likely wide swing of the N-term helix between the GTPγS-bound 
and active structures (Figure 3-3b)189. It should also be noted that activation caused the 





of β2-subunit in light purple), α5, and its N-term loop (red helix). The computational part of 
this project has been a collaborative work between our laboratory and Dr. Marta Filizola’s 
laboratory at Mt. Sinai School of Medicine; Dr. Davide Provasi from the Filizola laboratory has 
kindly generated the graphics for Figure 3-3.  
Figure 3-3 Gs movement within the heterotrimer G protein before and after activation. 
a) Insertion sites for biosensors are represented by blue balls with the ones of particular 
experimental interest highlighted by colored squares (color codes for #7, 67, 71, 99, 154, 175 
are those used for Figures 3-4-3-6) in (a) GTPγS-bound Gs structure (Sunahara et al., 1997) 
and (b) active Gs structure (Rasmussen et al., 2011). Different α-helix and β-sheet secondary 
structures are represented by different colors. The β1 subunit and γ2 subunits in the 
background are shown in light purple and light magenta, respectively. The co-crystalized 






Utility of different insertion positions and differences in conformational change of Gs between 
D1R and A2AR 
Using the created biosensors, two modes of relative proximity were studied – 
receptor-Gα coupling and Gα-γ subunit activation. Based on the extent of drug-induced 
BRET, two criteria were set and those that did not satisfy these criteria were not pursued 
further. The criteria were: 1) Drug-induced BRET of >0.005 at the highest agonist 
concentration, and 2) convergence of points to fitted curve. All the generated sensors 
were expressed well in cells based on the fluorescence or luminescence value. 
Nevertheless, introduction of the sensors may abrogate certain structural features, 
potentially leading to a dramatic drop in G protein coupling or activation. The absence of a 
drug-induced BRET signal does not establish that the G protein was nonfunctional, but 
since it was not a useful readout for our studies, these G protein constructs were not 
studied further. As a result, data from constructs #131, #305, #338 and #349 in Gs short 
are not shown. Particularly, in the case of #338 and #349, the sensor introduction may 
have interfered with receptor coupling (#338) and nucleotide-binding to the GTPase site 
#349) as these positions overlap with corresponding interaction sites. 
First, BRET1 between Receptor-RLuc8 and Gα-Venus was tested for D1R (Figure 3-
4a) and A2AR (Figure 3-5a). Note that different inserted positions are color-coded 
(7=black, 67=orange, 71=blue, 99=red, 154=green, 175=yellow) in Figures 3-4-3-6. In D1R, 





drug-induced BRET changes were similar, whereas #154 (also α-helical domain) showed a 
dramatic increase in BRET signal. #7 (N-term helix) showed slight negative BRET at higher 
agonist concentrations. A similar pattern of agonist-induced BRET was observed in A2AR 
except that the overall signals were smaller. Since the donors were different the size of 
the BRET signal cannot be compared directly.  The dramatic drug-induced BRET increase in 
both D1R and A2AR in #154 can be accounted for by the outward position of that 
particular residue within the α-helical domain (Figure 3-3b). Formation of the receptor Gs 
complex makes position #154 the closest to the base of the receptor amongst the 






Figure 3-4 D1R-activated Gs movement is detected in α-γ subunit BRET and Receptor-G 
protein BRET. 
a) Conformational change between the D1R and α subunit was measured by BRET1. b) 







Figure 3-5 A2AR-activated Gs movement is detected in α-γ subunit BRET and Receptor-G 
protein BRET. 
a) Conformational change between the A2AR and α subunit was measured by BRET1. b) 






Next, BRET2 between Gα-Rluc8 and γ2-GFP10 was used for D1R (Figure 3-4b) and 
A2AR (Figure 3-5b). In D1R, #67 and #71 had positive agonist-induced BRET with a strong 
dynamic range, while other sensor positions had negative BRET of <0.03. The positive and 
negative numbers reflect closing in and pulling apart between the donor (Gα-Rluc8) and 
the acceptor (γ2-GFP10) in either distance or orientation. The strong induced-BRET 
correlates with the predicted large movement during the G protein activation191. The 
positive BRET for #67 and #71 do not agree with the conventional theory that the G 
protein heterotrimer dissociates to Gα and βγ subunits upon receptor activation and GDP-
GTP exchange47. However, this activation model remains under active discussion and is 
not universally accepted47, 197, 198. It is possible that rather than completely dissociate from 
each other the Gα and βγ subunits after receptor activation heterotrimeric complex 
undergo a conformational change and dissociate from the receptor as a complex and 
couple to effector molecules198. Although it was not solved in the crystal structure, the 
downward movement of the loop between Ras and α-helical domain can be extrapolated 
from the GTPγS-bound and active Gs structures (Figure 3-3 dotted light blue). This 
movement brings the sensor close to the N-terminus of the γ2-subunit (where GFP10 is 
fused). Therefore, the positive BRET can be interpreted as a movement of Gs in the non-
dissociating heterotrimer. The negative BRET seen in #7, #99, and #154 could represent α-
γ subunit dissociation, but along the same line of argument, it can be also interpreted as 





is still associated. It should be also noted that between short and long isoforms, the same 
position in Gs short gave a better dynamic range (Gs short #99 [Figure 3-4b] vs. Gs long 
#113 [Figure 2-1e]) possibly suggesting a lesser degree of movement in the α-helical 
domain for the long isoform. Robust agonist-induced-BRET in #154 is consistent with the 
movement extrapolated from hydrogen-deuterium exchange studies191. 
In A2AR, #67 and #71 also showed positive BRET, which is consistent with the Gs 
movement in D1R. However, the dynamic range was much smaller for A2AR (Figure 3-5b, 
notice the different Y-axis scaling). On the other hand, #99 and #154 did show a good 
amount of negative BRET. The lack of drug-induced BRET in #175 may be due to the 
sensor orientation that faces away from γ2 both in inactive and active structures. 
Comparison between D1R and A2AR revealed differences in relative BRET 
amplitude (Figure 3-6). It should be emphasized that results obtained using different 
biosensors cannot be directly compared since different biosensors have different RET 
properties (e.g. sensor orientation). Results with of the same biosensors can be compared 
more readily despite some caveats. For example, α-γ BRET using Gs-Rluc #67 and GFP10-
γ2 from two different experiments can be compared if the expression levels of receptor, 
donor and acceptor are equivalent between the two experiments. In the case of the 
experiments described, the donor and acceptor expression levels were controlled by 
monitoring luminescence and fluorescence, but receptor expression was not measured, 





BRET max.  Nonetheless, relative differences of various biosensors within D1R 
experiments and A2AR experiments can be compared qualitatively. In other words, the 
absolute BRET values cannot be compared between D1R and A2AR, but the relative 
changes in BRET max seen with different sensors can be compared between D1R and 
A2AR because the expression levels of D1R (or A2AR) are likely to be be similar in all the 
D1R (or A2AR) experiments given the identical transfection conditions. That the positive 
BRET changes were much greater for D1 for sensors #67 and #71 whereas  the negative 
BRET change with sensor #154 was smaller for D1R cannot readily be explained by 
differences in receptor expression. Thus, while further studies with controlled receptor 
expression are essential, the evidence to date points to differences in the degree of Gs 
movement upon activation by D1R and A2AR. The lesser dynamic range of #67 and #71 in 
A2AR may be explained by less movement in the loop between Ras and α-helical domain. 
On the other hand, the α-helical movement (#99 and 154) induced by A2AR activation are 
slightly greater than with D1R activation. Therefore, the extent of movement of these two 
domains is likely different between D1R and A2AR. This is further confirmed by 
comparison between these receptors and β2AR (data not shown). To my knowledge these 
are the first data that suggests that different receptors produce different detailed patterns 
of activation of the same G proteins. This may result from differences in exact contacts 
between receptor and G protein or may possibly relate to differences in the dynamics of 
the movements. Additional structural analysis and computational simulation will be 






Finally, data from the Golf sensors are not shown because their dynamic range was 
<0.005 for all the created sensors in both receptor-Gα and Gα-γ BRET configurations. 
However, it should be noted here that they did show good drug responsiveness with β2 
adrenergic receptor (data not shown). This indicates that the Golf sensors are active. Small 
amplitude in the conformational change in A2AR and D1R may be due to the differences in 
expression level of interacting proteins and/or cellular environment between the native 
Figure 3-6 Differential movements are apparent between D1-activated and A2A-activated Gs 
subunit in α-γ subunit BRET. 





neuron and heterologous expression cell. Indeed Gβγ subunit expression pattern is quite 
different in HEK cells199 compared to the stratum and nucleus accumbens38. In these brain 
regions, A2AR and D1R are reported to functionally interact with β1γ736, 37, β2γ736, 37, and 
β4γ1200. While β1γ2, the most widely expressed subunit pair in the brain, was used 
throughout the thesis, the mVenus-γ7 construct was generated and compared in the light 
of previous reports36, 37. Preliminary results showed that BRET between Golf and γ7 was 
equally low as Golf γ2 pair (data not shown). More work is needed to identify optimal Golf 







Part 2: Elucidation of functionally coupling G proteins in A2AR-D2R heterodimer 
Investigation on the receptor functionality of A2AR in the A2AR-D2R heterodimer 
Close interaction of A2AR-D2R in MSNs146 and its heteromerization interface in an 
in vitro model153, 154 have been shown. Also, cross modulation between the two receptors 
at a functional level has been actively studied150-152. However, currently available assays 
have been limited in their abilities to accurately study A2AR-D2R heterodimer-specific 
signaling events as described in Chapter 2. We therefore used CODA-RET G protein-
coupling configuration to study this putative heterodimer. 
After extensive expression profiling of different constructs (i.e. modification of N-
term and C-term), 3xHA-A2A receptor (the same construct used in Part 1) was C-
terminally fused to Rluc8, L1 (N-term split of Rluc8), or L2 (C-term split of Rluc8). Agonist-
induced Gs-coupling to A2AR was confirmed and blocked in the presence of 1 µM 
antagonist SCH442416 (Figure 3-7a). In the CODA-RET configuration, A2AR-A2AR 
homodimerization was also shown to couple to Gs after agonist stimulation. Moreover, 1 





Using the same D2R-L1 and D2R-L2 split constructs from Chapter 2, heterodimer 
complementation level was studied between D2R and A2AR (Figure 3-8). These are plots of 
surface expression against complemented L1-L2 levels. Different ratios of DNA for D2RL1 and 
A2ARL2 (Figure 3-8a) and A2ARL1 and D2RL2 (Figure 3-8b) were transfected and their surface 
expression levels were determined by fluorescence activated cell sorting (FACS) using specific 
antibodies (αHA for A2A and αflag for D2). The X-axis is represented by the ratio of the surface 
expression between the two. More D2 (flag-tag detection) expression is shown to the right of the 
X-axis in Figure 3-8a and more A2A (HA detection) expression is found to the right of the X-axis in 
Figure 3-7 HA-A2AR constructs show Gs-coupliing. 
a) HA-fusion to the N-terminus showed drug induced BRET that was blocked by an antagonist. 
b) In CODA-RET configuration, HA-fused A2A-A2A homodimer showed drug induced BRET that 






Figure 3-8b. The Y-axis represents the luminescence from the complemented L1-L2, an indication 
of how well the receptors form heterodimers. The DNA transfection ratios giving the highest 
luminescence were chosen for D2RL1-A2ARL2 (Figure 3-8a, red circle) and A2ARL1-D2RL2 (Figure 
3-8b, red circle). They were 2.5 µg : 2.5 µg (=D2RL1:A2ARL2) and 3.3 µg : 1.7 µg (=A2ARL1:D2RL2) 
in 20 µg total transfection mix. 
Having established that the complemented A2AR-D2R heteromers expressed on the 
surface, CODA-RET was next conducted between A2AR-D2R heterodimer and Gs in both 
orientations (i.e. D2RL1-A2ARL2 and A2ARL1-D2RL2) with the optimized amounts of DNA (Figure 
3-9). To our surprise, agonist-induced Gs-coupling (insertion #71) was not observed in both 
orientations (Figure 3-9 orange) while Gi-coupling to D2R was intact in the same heterodimer unit 
(Figure 3-9 black). These results were puzzling since Gs-coupling to A2AR was active in A2ARL1-
A2ARL2 CODA-RET (Figure 3-7). The presence of D2R may decrease the affinity of Gs to A2AR, or 
the complemented luciferase might be positioned so as to not effectively BRET with the Gs sensor 
despite its ability to BRET with the Gi sensor. Neither of these problems were observed in the D1R-





To explore the A2AR-D2R signaling further, we opted to use the newly developed more sensitive 
Gs biosensor. 
After the entire Gs short constructs as well as the Golf constructs were made available, 
receptor-G protein BRET was reassessed with each insertion position in monomer (i.e. A2AR-RLuc8 
Gs-mVenus or Golf-mVenus) configuration (Table 3-1a) and homodimer (i.e. A2ARL1 A2ARL2 Gs-
mVenus or Golf-mVenus) configuration (Table 3-1b).  As shown in Figure 3-5a green, Table 3-1 
Figure 3-8 A2AR-D2R split constructs are expressed on cell surface and complemented well. 
a) In SF-D2sL1 HA-A2A-L2 coexpression, after titrating SF-D2sL1 with fixed HA-A2AL2, the 
transfected ratio for best cell surface expression was determined 2.5 μg : 2.5 μg (=SF-D2sL1:HA-
A2A-L2) in 20 μg total transfection mix. B) Likewise, in HA-A2A-L1 SF-D2sL2 coexpression, the 






blue, #154 gave a response and showed the best sensitivity in both full length Rluc8 and split 
Rluc8. 
Finally, heterodimer Gs-coupling was tested in the CODA-RET configuration. Amongst 
those tested, #154 provided the most clear-cut signal in the D2RL1-A2ARL2 orientation (Table 3-2, 
Figure 3-10). Agonist-induced BRET was inhibited by its specific antagonist, SCH442416. For 
efficacy and potency comparison, a drug response curve for A2ARL1-A2ARL2 homodimer with the 
same Gs-mVenus sensor #154 was shown (Figure 3-10 black). Remarkably, the potency was 
approximately the same between the homodimer and the heterodimer and the dynamic range 
was also similar. The better relative sensitivity of #154 sensor in the heterodimer is intriguing and 
may result because #154 residue is close to the A2AR in the active conformation (Figure 3-3). 
Taken together, A2AR in the A2AR-D2R heterodimer is indeed functional and its Gs-coupling with 
the #154 sensor is roughly similar to that seen with the A2AR homodimer. This CODA-RET 
configuration may therefore serve as an assay in future experiments designed to tease out the 
aforementioned cross modulation mechanisms in A2AR and D2R co-expressed cells150-152.  
Figure 3-9 Gs-coupling is not observed in HA-A2AR-D2R heterodimers. 
a) Agonist-induced BRET was not observed in SF-D2L1 HA-A2AL2 heterodimer. b) It was not 







Table 3-1 Insertion position at 154 a.a. gives the best response as a BRET pair. 
a) Both Gs and Golf biosensors inserted at various positions were tested for receptor-G protein 
coupling configuration. In both a) full length Rluc8 and b) split Rluc8, Gs-Venus inserted at 154 
a.a. gave the best response. ‘+’ indicates a drug-induced BRET response (+++>++>+). ‘0’ indicates 







Figure 3-10 Insertion position at 154 a.a. shows Gs coupling to D2R-A2AR heterodimer. 
Gs-coupling level in D2R-A2AR heterodimer was comparable to A2AR-A2AR homodimer. The 
antagonist blocked the agonist induced Gs-coupling. 
 
Table 3-2 Insertion position at 154 a.a. 
shows Gs coupling to D2R-A2AR 
heterodimer. 
Amongst the all combinations tested, SF-
D2RL1 HA-A2ARL2 Gs154-Venus gave a 






Discussion (Chapter 3) 
A2AR is a pharmacologically well-characterized receptor201. Its signaling aspects have been 
studied as a prototypical Gs-coupled receptor202 and it’s also well-studied structural properties 
have been made more clear by recent advances in both antagonist203, 204- and agonist205, 206-bound 
crystal structures. However, much like other Gs-coupled receptors, the extent of conformational 
changes in Gs via activated A2AR remains unknown. This has relevance in signal transduction as Gs 
in different conformations may couple effectors differently, thus determining the relative strength 
and/or bias of signal activation. The new series of Gs biosensors made here has revealed a distinct 
pattern of conformational movements mostly consistent with the differences between GTPγS-
bound Gs crystal structure190 and the recent β2AR-Gs crystal structure189. It is intriguing that the 
relative BRET differences amongst the sensors were different between A2AR and D1R – 
particularly the difference between insertion positions in the α-helical domain and the linker 
between the α-helical domain and Ras domain. The movement of α-helical domain is correlated 
with GTP-GDP exchange47. Thus, the difference observed between A2AR and D1R may be one of 
the underlying mechanisms for Gs-effector activation differences. 
The recent β2AR-Gs crystal structure demonstrated that the predicted α-helical domain 
movement in the receptor-Gs complex was indeed in the flipped-up position. However, the overall 
conformational change of heterotrimeric G protein in the crystal structure needs to be interpreted 
carefully since it was solved with a nanobody, which served as a supporting structure for the 
heterotrimer complex formation. Although the presence of nanobody was described as not 
introducing a steric clash to the structure, its presence likely affected the conformation of the βγ 





without the structural stabilization provided by the nanobody may be α-helical domain movement 
followed by βγ-subunit dissociation, as the sequence of G protein activation is thought to require 
dissociation of the heterotrimeric subunits in order for the Gα to couple to an effector molecule207 
47. Although consistent with the classical mechanism, this view has also been challenged by the 
claim that G proteins can function as intact heterotrimers197, 198. The claim implies that the 
heterotrimer leaves the receptor docking site and couples to an effector without undergoing 
subunit dissociation. Therefore, both dissociated and non-dissociated Gα subunits are 
functional208 and it is likely that in reality both forms of Gα exist as signaling units in the same cells. 
In analyzing Gα-γ BRET results (Figure 3-6) of positions #67 and 71, non-dissociation 
conformational change is likely in these sensors. This is because if the α-helical movement 
uncovers the linker between the Ras and α-helical domains, the BRET between Gs and γ subunit 
increases. However, it cannot be denied that the presence of sensor proteins somehow prevented 
subunit dissociation. Positions #7, 99, and 154, on the other hands, showed negative BRET and this 
can be interpreted as either dissociation or non-dissociation. Overall, these biosensors may not 
function as surrogates for actual Gs dissociation/non-dissociation status. Nevertheless, they can be 
useful tools to fingerprint different receptors for their conformational changes within Gα. 
Especially, the movement of α-helical domain (open clam shell) is linked to GTP-GDP exchange47. A 
study shows that the kinetics of PKA activation (downstream of Gs-coupling) by A2AR is longer 
than D1R209. Besides the suggested slow internalization rate of A2AR209, long activation kinetics 
can be attributed to the more efficient AC activation and subsequent PKA activation. Although 
speculative, the pronounced α-helical movement may be linked to better nucleotide exchange and 





 The sensor #154 proved to be very valuable as its dynamic range in both receptor-Gα and 
Gα-γ BRET was better than the other sensors (Figures 3-4, 3-5). More importantly in A2AR-D2R, it 
showed functional coupling demonstrating that A2AR-D2R dimer is a functional signaling unit for 
both Gi and Gs signaling. Therefore, the sensor #154 may be used for studying other Gs-coupled 
heterodimers (e.g. adenosine A1R-D1R). Also the sensor (or the sensor position) should be used 






Chapter 4 : Mechanism for dopamine induced calcium release 
 
Background and significance (Chapter 4) 
As pointed out in the introduction, one of the major confusions in the field of DA receptor 
research is that there are several different mechanisms proposed for DA stimulated internal 
calcium mobilization both in vitro and in vivo. It is of our particular interest to elucidate the actual 
calcium triggering mechanism upstream of IP3R in both heterologous and primary culture cells. DA 
mediated calcium release is potentially important in MSN physiology, which is connected to 
understanding neurological and psychiatric illnesses. One of the proposed mechanisms involves 
receptor heterodimerization between dopamine D1R and D2R. We first looked for evidence of 
D1R-D2R receptor colocalization in the striatum of mouse as well as in MSN primary culture. 
Because of our inability to detect such colocalization, we studied alternative mechanisms for 
calcium release mechanisms that do not involve D1-D2 heteromerization. Finally, the key link 








Results (Chapter 4) 
 
Part 1: Investigation on D1R-D2R colocalization in the striatum and NAc 
Assessment of D1R- and D2R-promoter driven fluorescent reporter expression in the striatum 
Introduction of a long DNA sequence by bacterial artificial chromosome (BAC) injection to 
create transgenic mice has proven to be extremely useful, as demonstrated in particular by the 
efforts of Gene Expression Nervous System Atlas (GENSAT) to visualize specific gene expression 
patterns in nervous system210.  They have generated a library of BACs that were introduced to 
mouse lines, and each of these mouse lines has a fluorescent protein transgene specifically 
expressed at loci determined by transcription regulatory elements in the BAC. In drd1a-Tomato 
mouse, the injected BAC is made of ~100 kbp DNA sequence within the vicinity of D1R except that 
the D1R gene itself was replaced by the gene encoding red fluorescent protein tdTomato. This 
allows the expression of soluble tdTomato protein in cells in which D1R transcription is driven. On 
the other hand, in drd2-EGFP, EGFP is expressed in D2R expressing cells. After generation of a 
combined line (i.e. drd1a-Tomato/drd2-EGFP), the adult mice were sacrificed and the fluorescent 
signals were amplified using immunostaining to visualize for the reporter gene expression pattern 
(Figure 4-1). As seen in this horizontal section, tdTomato and EGFP were strongly expressed in the 
caudoputamen (CPu) of the striatum but in an essentially segregated pattern. In contrast, in the 
nucleus accumbens (NAc) shell high power magnification (60x images, Figure 4-1) revealed 
coexpression of both reporters in somas as well as projections (seen in yellow) in a fraction of the 
cells, consistent with previous findings14. Initial estimates of the degree of colocalization were: 





these neurons strongly suggests that the D1R and D2R may both be expressed in these yellow 
cells. 
Finding the level of D1R-D2R colocalization in the striatum 
  Next immunohistochemistry was performed in the same areas of interest in wild type 
(WT) mice using specific D1R and D2R antibodies that were validated using D1 and D2 knockout 
Figure 4-1 Horizontal slice of an adult BAC double transgenic mouse with zoom on the 
caudoputamen and the NAc shell. 
eGFP was expressed under the D2R promoter (green) and tdTomato was expressed under the 






mice (Figure 4-2). In accordance with the lack of reporter coexpression, D1R and D2R were 
segregated in the CPu. However, to our surprise, the receptors also appeared to be segregated in 
the NAc shell. We also performed immunostaining for both receptors in the NAc shell of the 
double-transgenic BAC reporter mice (Figure 4-3). A region in the NAc shell image (Figure 4-3a 
black square) was imaged at high magnification (Figure 4-3b). In Figure 4-3c, D1R (red, pseudo-
color) and D2R (green, pseudo-color) antibody-staining was visualized in the same image field as 
Figure 4-3b. The yellow signals in Figure 4-3b were overlaid on top of Figure 4-3c as a gray shade. 
This image processing allowed us to isolate D1R and D2R staining in dendritic areas that coexpress 
both reporters. As shown in Figure 4-3d, D1R and D2R were indeed coexpressed in yellow 
dendritic areas but showed, if any, a very low level of colocalization. This suggests that, even if 
both receptors are co-expressed in the neurons of the NAc shell, D1R and D2R appear to be 











Figure 4-2 D1R (red) and D2R (green) staining in the caudoputamen and the NAc shell. 
D2R staining is shown in green and D1R staining is shown in red. There is no co-localization of 







To further confirm the D1R-D2R colocalization or lack thereof in the striatal neurons, a 
proximity ligation assay (PLA) was used to specifically look for close proximity of the two 
receptors. The principle of the PLA methodology is reviewed in Figure 4-4. Consistent with the 
immunostaining results, no signal originated from a heteromer population between D1R and D2R 
(Figure 4-5a). As a positive control, colocalization of the A2AR and D2R was detected in the 
striatum as intense puncta (Figure 4-5b146). Finally, as a way to visualize D1R-D2R colocalization 
and confirm the interaction of D1R and D2R when coexpressed heterologously as in Chapter 2, 
HEK cells stably expressing the two receptors were used for immunostaining (Figure 4-6a) and PLA 
assay (Figure 4-6b). The same set of antibodies clearly detected the D1R (red) and D2R (green) on 
the surface of many cells and it was estimated >66% overlapped (Figure 4-6a). Detection of the 
heteromeric population was convincingly demonstrated in the PLA assay as well (Figure 4-6b). In 
addition to supporting the existence of D1R-D2R oligomers in HEK cells, these experiments rule 
out the possibility that the lack of D1R-D2R colocalization and close proximity on striatal slices 
could be due to the masking of antigenic sites by oligomer formation. These sets of results from 
brain slice and stable cells reveal the complexity of subcellular protein sorting in the native 
Figure 4-3 D1R and D2R staining in the NAc shell of BAC double-transgenic mice. 
  (a) Cells expressing GFP (green) under the D2R promoter and tdTomato (red) under the D1R 
promoter in the NAc shell. The black square shows the inset in (b). (c) Gray shaded regions 
represent the overlap of green and red from the image in (b). D1R staining is shown in red, 
D2R staining is shown in green. In (d) are shown D1R (red) and D2R (green) staining only in 






neurons that seem to separate the two receptors. But more importantly, they argue against the 
D1R-D2R heteromer population as a significant signaling platform in vivo even in cells in the NAc 
that express both receptors. Brain imaging was a collaborative project with Dr. Pierre Trifilieff.  
 
 
Figure 4-4 Principle of Duolink proximity ligation assay. 
  (a) Two epitopes are detected by antibodies of different origin (e.g. mouse and rabbit). (b) 
Two species-specific secondary antibodies are conjugated with specially designed 
oligonucleotides. After binding of secondary antibodies to the primary antibodies, the specially 
designed circle forming DNA is added to hybridize with the conjugated nucleotides. If the two 
secondary antibodies are within sufficient proximity (i.e. <16 nm), then the DNA becomes 
circularized upon addition of a DNA ligase. (c) Addition of DNA polymerase amplifies the 
circularlized DNA. (d) Complementary fluorescent probes bind to the amplified DNA and can be 







Figure 4-5 D1R-D2R interaction is not detected in the striatum or NAc. 
 (a) PLA was used to detect interaction of D1R and D2R in the striatum or nucleus accumbens. 
There was no increase in pucta compared to the background control. (b) A2AR-D2R interaction 








Figure 4-6 D1R-D2R colocalization is detected in the D1R D2sR double stable HEK cells. 
 (a) Immunostaining using D1R and D2R antibodies showed clear colocalization in >66% of 
cells that stably express D1R and D2sR. (b) D1R-D2sR interaction was clearly detected by 






Part 2: Mechanisms of D1R- and D2R-mediated calcium mobilization – preliminary 
studies and future directions 
Proposed mechanisms of DA-induced intracellular calcium mobilization 
IP3-mediated calcium mobilization has been shown for both D1-like receptor33, 68 and D2-
like receptor57 -mediated mechanisms. Based on our inability to identify colocalization of D1R and 
D2R as discussed in the first part of this chapter, it seems unlikely that D1R-D2R heteromers are 
the origins of these signaling events in the striatum. Therefore, our focus turned to individual 
activation of D1R (Figure 4-7) or D2R (Figure 4-8). The activation of ER-store calcium release is 
regulated by ryanodine receptors and IP3Rs. GPCR-mediated signaling converges to IP3R activation 
through two pathways: 1) Activation of PLCβ via Gq- or βγ subunit-coupling, which subsequently 
stimulates IP3 production and therefore gates the IP3R, or 2) phosphorylation of the IP3R via 
kinase activation (e.g. PKA and PKC) which sensitizes IP3R to IP3 and thereby amplifies calcium 
release to an IP3 signal. In previous studies72, 73, “potentiation” referred to D1R-induced Gs-
mediated (i.e. PKA-mediated) activation of IP3R that did not occur through D1R activation alone 
but was “primed” by previous stimulation of a Gq-coupled receptor. However, such a potentiation 
of calcium mobilization could also result from a βγ subunit-dependent process whereby βγ 
subunit-mediated PLCβ activation is also primed by Gq activation211.  As shown in the diagrams, 
priming of PLC activation by Gq-coupled receptor followed by D1R (Figure 4-7) or D2R (Figure 4-8) 
activation could lead to calcium mobilization through two different signaling routes (indicated by 
question marks). Arrows with arrowheads indicate the activation and T-ends indicate the 







Figure 4-8 Proposed mechanism for IP3R activation via D2R-Gi/o stimulation. 





In Part2 of this chapter I will present preliminary experiments I have conducted to begin to 
address the mechanism by which dopamine receptors lead to calcium mobilization in both HEK293 
cell and medium spiny neurons. It should be emphasized that this work is of a preliminary nature 
Figure 4-7 Surface expression of D1R and D2R in three different stable cell lines generated. 
Using FACS analyses, cell surface expression levels of corresponding receptors are shown. (a) 
αHA antibody was used to detect HA tagged D1R. From left, D1/T NO and D1/T IND indicate 
cells expressing D1R under tetracycline induction promoter (=D1R stable) without (NO) and 
with (IND) 1 μg/ml tetracycline induction. D2/P D1/T NO and D2/P D1/T IND indicate cells co-
expressing D1R under tetracycline induction and D2sR (= D2R D1R stable) without (NO) and 
with (IND) 1μg/ml tetracycline induction. (b) αflag antibody was used to detect flag tagged 
D2sR. From left, cont indicates HEK blank cell control. D2/P D1/T NO and D2/P D1/T IND are as 
described. D2/P indicates D2sR stably expressed cells (D2R stable). Y-axis is the mean 






that has just begun to address these issues by exploring some of the signaling components.  
 
Acetylcholine potentiates the DA-induced calcium effect 
 In order to maintain consistent receptor expression levels for the calcium assays, stable 
cell lines were generated for HA-D1R, flag-D2sR, and HA-D1R/flag-D2sR-coexpressing cells and 
tested for their cell-surface expression levels (Figure 4-9). D1R expression (detected by αHA 
antibody) in D1R and D1R/D2R-coexpressing cells showed similar levels of expression after 
overnight tetracycline induction (Figure 4-9a). D2R was also expressed well in D2R and D1R/D2R 
cell lines (Figure 4-9b). Using these three cell lines and control HEK cells, ligand-stimulated 
intracellular calcium levels were measured on a Flexstation3 (Figure 4-10). Cells were distributed 
in 96 well plates, incubated in Flipr5 calcium dye for loading, and subjected to ligand injections at 
the times indicated. First the effect of 10 µM DA on intracellular calcium mobilization was 
measured, but there was no calcium response (Figure 4-10 top row). Next, the Gq-mediated 
calcium response was tested with 10 µM acetylcholine (ACh) to stimulate endogenous muscarinic 
receptors (Figure 4-10 middle row), as M3 muscarinic receptors are widely expressed in HEK 
cells199. A clear pattern of robust and prolonged (>60 secs to subside) internal calcium release was 
observed, with kinetics consistent with IP3R-mediated calcium mobilization65. The response was 
blocked by the muscarinic receptor-specific antagonist pirenzepine (data not shown). To test the 
possibility of Gq priming in these cells, DA was added 80 secs after addition of ACh. This triggered 
a calcium response robustly in all the cell lines, but not the control parental HEK cells, consistent 
with the existence of both D1R- and D2R-dependent mechanisms for calcium mobilization after Gq 






Figure 4-8 DA receptor-mediated calcium response after ACh priming. 
Intracellular calcium levels were measured every 2 seconds and plotted against time. Ligands 
(Veh = vehicle control, Ach = 10 μM acetylcholine, DA = 10 μM dopamine) were added at 20 
secs and 100 secs, indicated by arrows, in (a) HEK blank cells, (b) D1R, (c) D2R, and (d) 
D1R/D2R stable cells. Traces are representatives of n = 3 or more experiments. Scale bar reads 
30 secs x 100 RFU. If not noted otherwise, drug concentration of 10 μM was used for injected 






 To ensure the receptor specificity, different selective agonists were tested for their ability 
to trigger a response after priming. In D1R cells, after ACh priming, both SKF83959 and SKF81297 
(D1R agonists) led to the calcium effect (Figure 4-11a) while the D2R-selective agonist quinpirole 
did not. In contrast, quinpirole produced the effect in D2R cells (Figure 4-11b). SKF83959 is known 




Figure 4-9 D1R- and D2R-selective agonist-mediated calcium response after ACh priming. 
Intracellular calcium levels were measured every 2 seconds and plotted against time. Ligands 
(Veh, ACh, 83959 = SKF83959, 81297 = SKF81297, Quin = quinpirole) were added at 20 secs and 
100 secs, indicated by arrows, in (a) D1R and (b) D2R stable cells. Traces are representatives of 






Elucidation of ‘potentiation’ mechanism 
 Next, the involvement of PLC activation was addressed using the antagonist, U73122 
(Figure 4-12). In all the cell lines, 10 µM U73122 abrogated ACh-mediated internal calcium 
mobilization as expected. The subsequent DA effect was also blocked by U73122 in all the cells. 
This is consistent with the hypothesis that PLC activation is essential for both the ACh and 
subsequent DA effects. 
 To further confirm receptor specificity, selective antagonists were added prior to receptor 
stimulation with the agonists to inhibit the D1R- and D2R-activated calcium effect. As expected, 
both in D1R and D2R cells the potentiated calcium effects were blocked by the cognate 
Figure 4-10 Both ACh priming and DA response are PLC-mediated. 
Intracellular calcium levels were measured every 2 seconds and plotted against time. Ligands 
(ACh and DA) were added at 20 secs and 100 secs, indicated by arrows, in (a) D1R, (b) D2R, and 
(c) D1R/D2R stable cells. Top and bottom rows are without and with 15 mins preincubation of 
10 μM U73122 (PLC inhibitor). Traces are representatives of n = 2 experiments. Scale bar reads 






antagonists (Figure 4-13a-b). Treatment with cholera toxin was used to constitutively ribosylate 
the Gs subunit to block receptor-mediated activation of Gs. This led to a loss of the D1R agonist 
effect after priming (Figure 4-13c), consistent with the involvement of the cognate coupling 
protein Gs in the process. Similarly, pertussis toxin was used to block Gi activation and this also 
blocked the D2R agonist effect after priming (Figure 4-13d). 
Figure 4-11 Requirement of receptor and G protein activations in D1R and D2R cells. 
Intracellular calcium levels were measured every 2 seconds and plotted against time. Ligands 
(ACh, Veh, Quin, 81297, and 83959) were added at 20 secs and 100 secs, indicated by arrows, 
in (a,c) D1R, (b,d) D2R stable cells. In bottom row, cells were pretreated by (a) 10 μM 
SCH23390 (15 mins), or (b) 10 μM sulpiride (15 min), (c) 10 μg/ml cholera toxin (overnight), (d) 
100 ng/ml pertussis toxin (overnight). Traces are representatives of n = 2 or more 






To rule out the specific involvement of muscarinic receptors in the Gq priming process, a 
different Gq-coupled receptor was activated to test if that provides the same potentiation effect 
to DA receptors. There are endogenous purinergic receptors (particularly Gq-coupling P2Y11 
receptor) in HEK cells199, therefore, its agonist ATP was used to test the idea. In the D1R/D2R cells, 
10 µM ATP gave a similar kinetic profile of calcium rise as 10 µM ACh and subsequent D1R/D2R 
agonist stimulation was successfully potentiated (Figure 4-14a). This suggested that Gq activation 
was the principle mechanism for the potentiation. The blockade of D1R-mediated calcium effect 
by cholera toxin (Figure 4-13c) also suggested a role of Gs activation as the mechanism and not 
another D1R-interacting protein. To this end, an endogenous Gs-coupled receptor β2 adrenergic 
Figure 4-12 Gq potentiation and Gs activation can be triggered by different receptors. 
Intracellular calcium levels were measured every 2 seconds and plotted against time. Ligands 
(ATP, ACh, Quin/81297 = 10 μM quinpirole + 10 μM SKF81297, ISO = isoproterenol) were added 
at 20 secs and 100 secs, indicated by arrows, in D1R/D2R stable cells. (a) Cells were primed by 
ATP (instead of ACh) and stimulated by Quin/81297. (b) Cells were primed by ACh and 






receptor199 was stimulated with 10 µM isoproterenol (ISO) following ACh priming and it also 
showed  a similar intracellular calcium release (Figure 4-14b) confirming that Gs activation from at 
least two different receptors causes calcium effects after Gq priming.  
The reported D1R- 33, 67, 68, 75-77 and D2R- 57, 70, 75 mediated calcium mobilization responses 
were observed with relatively high concentrations of selective agonists. For the most part calcium 
effects were seen at a concentration of 10 µM or more. Given reports that high concentrations of 
DA can increase calcium without a priming protocol33, 57, 67, 68, 70, 75-77, we explored an even higher 
concentration 100 µM to see if this concentration could trigger the calcium response without the 
potentiation. In D1R cells, either 100 µM DA or SKF81297 showed a calcium response (Figure 4-
Figure 4-13 Receptor activation at a high agonist concetration triggers calcium response 
without priming in D1R and D2R-D1R cells. 
Intracellular calcium levels were measured every 2 seconds and plotted against time. Ligands 
(Veh, 100 μM DA, 100 μM 81297, 100 μM Quin, 100μM Quin + 100 μM 81297) were added at 
20 secs and 100 secs, indicated by arrows, in (a) D1R, (b) D2R, and (c) D1R/D2R stable cells. 






15a). In contrast, neither 100 µM DA nor quinpirole caused a calcium response in D2R cells (Figure 
4-15b). Finally, D1R/D2R cells were studied with either 100µM DA or co-stimulation by selective 
agonists (100 µM SKF81297 + 100 µM quinpirole) (Figure 4-15c). Here, the effects were about the 
same as D1R cells (Figure 4-15a) suggesting that the stimulation of D2R did not enhance the 
intracellular calcium signal, a finding at odds with previous reports using D1R-D2R heteromers213, 
214.  
In line with the parallel results in primed D1R and D2R cells, one attractive candidate that 
is shared by both D1R- and D2R-mediated pathways is Gβγ subunit activation and interaction with 
PLCβ215. Small molecule inhibitors have been developed for blocking this interaction by binding to 
the β-subunit39, a known interface between Gβγ and PLCβ216. Reportedly functional compounds39, 
217 were tested for their ability to block the D1R- and D2R-mediated calcium response after initial 
activation of Gq by ACh. Both in D1R (Figure 4-16a) and D2R cells (Figure 4-16b), 10 µM Gβγ 
inhibitors were able to reduce the potentiated response. There seemed to be varied responses 
amongst the different compounds (Figure 4-16c), which could conceivably be accounted by 
different βγ subunit specificity in the G protein heterotrimer complex, although the limited 
characterization of these compounds makes it difficult to establish what might be off target 
effects. This requires substantial further investigation and quantitative analyses of these data will 
have to be conducted to draw mechanistic conclusions. Nonetheless, these qualitative preliminary 
results provide a mechanistic model for the potentiated response: Gβγ interaction with PLCβ 
activates IP3R-dependent intracellular calcium release. Gβγ-PLCβ interaction is known to activate 
PLCβ by itself215, 216 or in conjunction with Gq activation211, 218, consistent with the results shown 





activate PLCβ (Figure 4-15). The potentiated response can be explained by either the proposed 
simultaneous binding of Gq and Gβγ subunit to PLCβ211, 218 or Gβγ binding to a high affinity PLCβ 
(due to priming by Gq). Proximity based biophysical assays (e.g. BRET) may be able to distinguish 
Figure 4-14 βγ signaling blockers inhibit DA-mediated calcium response. 
Intracellular calcium levels were measured every 2 seconds and plotted against time. Ligands 
(ACh and DA) were added at 20 secs and 100 secs, indicated by arrows, in (a) D1R and (b) D2R 
stable cells. In the bottom row, cells were preincubated for 15 mins in 10 μM βγ inhibitors – (a) 
gallein and (b) M201. Summary of other purported βγ inhibitors is shown (c), where ‘0’ = no 
inhibition of DA-mediated calcium response, ‘-’ = inhibition of DA-mediated calcium response, 
and ‘-(ACh)’ = inhibition of both ACh and DA-mediated calcium response. Traces are 








Potentiation effect in primary striatal neurons 
One of the goals of neuropharmacology research is to test if the mechanisms found in in 
vitro settings are relevant to cells in a more native environment. To this end, we prepared cultures 
of medium spiny neurons (MSNs) from postnatal day 1 mice. First, the expression patterns were 
studied in the prepared 2 week-old culture (Figure 4-17). D1R (green) and D2R (red) were detected 
by corresponding specific antibodies. They both expressed highly and immunopositive somas and 
projections were almost entirely segregated, much like in the adult striatal slice (Figure 4-2). Using 
the same 2 week-old striatal culture on a coverslip with a bed of astrocytes, calcium imaging was 
conducted with a multiphoton microscope. Cells were loaded with fluorescent calcium dye (Asante 
calcium red, see methods) and placed in a chamber containing buffer with antagonists for GABAA, 







Figure 4-15 Lack of D1R-D2R colocalization in medium spiny neuron primary culture. 
Using specific antibodies, (a) D1R and (b) D2R were visualized (20x magnification) in two week 








Cultured cells were imaged after a local DA puff application at the indicated time points 
(Figure 4-18a). The plot shows the average intensity of ten MSNs over time. Cells were chosen 
based on morphology (Figure 4-17) as well as the location (on top of glial cells).  Three consecutive 
puffs of 1 mM DA failed to trigger a calcium response in ten cells. Although the concentration of 
DA in the pipette was high, given the very small released volume of each puff (<100 nl), diffusion 
in the buffer makes the local concentration exponentially small as it travels further away from the 
pipette. Therefore, the concentration that receptors see should be much smaller than 1 mM since 





MSNs express variety of different Gq-coupled receptors (e.g. mAChR, mGluRs, P2Ys). 
Taking advantage of the fact that they receive cholinergic inputs and thus express muscarinic 
receptors, the cultured cells were stimulated with 10 µM ACh by bath perfusion (Figure 4-18b). 
The gradual increase in the averaged ten cells is shown in the graph (Figure 4-18b). Although data 
are not shown, individual cells exhibited an oscillating pattern  of calcium response throughout the 
Ach perfusion, which is consistent with IP3R-mediated calcium mobilization kinetics also seen in 
other cell types65. 
Having been able to see the calcium increase in ACh treated cultured neurons, we puffed 
DA during ACh perfusion (Figure 4-18c-d). Consistent with the HEK stable cell results, many cells 
responded to each DA puff (indicated by arrows) after ACh priming. The plot is the average of ten 
responsive cells indicated in Figure 4-18c (note the end of the pipette is also in the field). The 
kinetic profile of calcium signals (i.e. amplitude and duration) coincides with a slow IP3R-mediated 
one rather than a channel-mediated spike pattern (Figure 4-18d). These results in primary striatal 
Figure 4-16 Apparent DA-induced calcium release after ACh priming in medium spiny neuron 
primary culture. 
Calcium levels were measured and the average of ten cells against time was plotted in three 
different conditions. (a) 1 mM DA (<100 nl) was locally applied by picospritzer at indicated time 
but invoked no response. (b) 10 μM ACh was perfused and increased the intracellular calcium 
level gradually. (c,d) 1 mM DA puffs elicited increases in intracellular calcium during 10 μM ACh 







culture suggests that the mechanism of potentiation of DA-stimulated response by Gq priming 
exists in the MSNs, although the molecular targets in the signaling (e.g. Gβγ-PLCβ interaction) 





Discussion (Chapter 4) 
 The apparent lack of colocalization of D1R and D2R in the striatum was unexpected given 
the results of BAC transgene overlap (Figure 4-3). As the visualization of receptors relied on 
specific antibody detection, non-specific staining and overexposure of images had to be carefully 
controlled. Perhaps, the disagreement between our findings and the published studies123, 213 can 
be attributed to differences in antibody staining, although the same antibodies were used. 
Nevertheless, the presence of both D1R and D2R staining in the yellow double transgene 
expressing cells (Figure 4-3d) is consistent with the coexpression of the two receptors in a subset 
of cells in the ventral striatum, consistent with the literature123. This raises a separate fascinating 
question in cellular biology as to how these two receptor species are segregated within the same 
neurons, whereas they are able to interact in HEK cells (Figure 4-6). 
  The apparent lack of D1R-D2R colocalization in the striatum  as well as our failure 
to detect a Gq signal from the heteromer in HEK cells where we knew that the heteromer was 
formed (Chapter 2) made us question the necessity of D1R-D2R heteromers for the reported 
intracellular calcium release9. In that study, costimulation of both D1R and D2R with either 
dopamine or two specific agonists activated calcium release. But the data in the same study also 
showed that the D1R agonist (SKF81297) by itself triggered significant calcium release. Our results 
are in line with this observation albeit at a high concentration (Figure 4-15a). Priming by Gq 
activation led to both D1R- and D2R-mediated calcium mobilization in HEK cells (Figure 4-10). 
Although further work is needed to elucidate the detailed mechanisms, results here point to the 
possibility of the βγ subunit’s involvement in PLC activation (Figure 4-16). Also it should be added 





both D1R and D2R cells (Figure 4-11 middle row). Consistent with this observation, SKF83959 was 
found to bind and activate both D1R-Gs and D2R-Gi coupling in BRET assays(Table 2-3), suggesting 
that the βγ subunit may be involved in the action of this drug as well. 
 The potentiation effects have been reported previously in terms of Gq priming a calcium 
response to D1R signaling. In this case, the D1R-mediated PKA-dependent phosphorylation of the 
IP3 receptor was implicated in the mechanism based on the ability of a PKA inhibitor to block the 
effect72, 73. Although we also observe a similar Gq priming effect on D1R signaling, very preliminary 
experiments indicate that it is not inhibited by a PKA inhibitor (data not shown). These preliminary 
data suggest that the priming signal may be occurring at the level of PLCβ.level. Reports have 
suggested that PLCβ-dependent IP3 production is significantly enhanced by co-activation of Gq- 
and βγ (βγ released from Gi)-coupling211, 218. The report also described that PLCβ may have two 
distinct binding sites for Gq and βγ allowing simultaneous activation by the two proteins211. 
Therefore PLCβ functions as a convergence point for the potentiation (crosstalk enhancement) 
effect. Our preliminary results are consistent with a role for βγ-subunit-dependent PLC signaling in 
calcium mobilization by both the D1R and D2R pathways (Figure 4-16). Finally, the potentiation 
effect was also observed in primary culture of striatal neurons (Figure 4-18). MSNs are known to 
receive cholinergic and glutamatergic efferents and express Gq-coupled receptors – mAChR, 
mGluRs, and others (e.g. purinergic P2Ys)20. As DA receptors can be found in the same dendrites as 
these receptors219, co-transmission of ACh or glutamate with DA to the same MSN would trigger 
intracellular calcium mobilization greater than either of the transmitter alone. Therefore, PLCβ 
could function as a coincidence detector for two different neurotransmitter inputs. As a result, the 












Chapter 5 : Conclusion 
One of the actively investigated areas in DA neurotransmission research is to understand 
functions of the DA receptor dimerization and higher order complex formations1. In order to fully 
understand the significance of widely reported GPCR dimerization phenomena3, 97, 220, signal 
transduction must be evaluated for each individual dimer pair. Unfortunately, because of the lack 
of methodology that can separate dimer-dependent signaling from homomeric signaling, this had 
not been possible. We have established a method to study G protein- and arrestin-coupling only in 
the defined heterodimer. In this thesis, we investigated DA dimer pairs that arise from co-
expressing D1R and D2R (i.e. D1R-D1R, D2R-D2R, and D1R-D2R) and found a unique D1R-D2R 
heterodimer-dependent functional selectivity in one of the D2R agonists. NPA showed an 
enhanced Gi-coupling in D1R-D2R heterodimer compared to D2R-D2R homodimer whereas other 
D2R agonists did not show the same effect. The potency shift in D1R-D2R heteromer, however, 
was not observed in other signaling pathways. We also studied another heterodimer that has been 
extensively studied, A2AR-D2R147, and showed, for the first time, a functional Gi- and Gs-coupling 
to the dimer. Taking advantage of the ability to study fine proximal relationship between two 
probes, BRET was further utilized for studying conformational changes in Gs. This work led to 
uncovering possible differences in the conformation of Gs when activated by D1R and A2AR, which 
may affect Gs-effector coupling. 
 Intracellular calcium level is a major regulator of synaptic plasticity that further 
determines the strength of neurotransmission10, 58. The other contentious area in DA receptor 
biology is the extent of DA receptor-induced calcium mobilization and the underlying mechanism1. 





including heterodimers9, 69 and the mechanism that can satisfy these different reports has not 
been found. We first investigated the native receptor expression levels in the striatum and NAc 
and found surprisingly no D1R-D2R colocalization in these areas, although abundant in co-
expressing HEK cells. This evidence along with the findings that there is no Gq-coupling in DA 
receptors questioned the idea that the D1R-D2R heteromers are needed to trigger calcium 
mobilization9. We conceptualized that the purported heteromer mechanism can result from the 
summation of D1R- and D2R-mediated pathways. Therefore, we began to study PLCβ activation by 
D1R or D2R when expressed alone. In preliminary experiments, I found that upon prior PLCβ 
activation (i.e. potentiation), there was a robust intracellular calcium release in either D1R- or 
D2R-dependent pathway. Therefore, the reported D1R-D2R activation-dependent calcium 
mobilization can be the result of summation or crosstalk between D1R and D2R costimulation. 
Although preliminary, the D1R- or D2R-activation appears to trigger Gβγ-mediated PLCβ activation 
in HEK cells. The potentiation mechanism was also observed in MSNs, making the calcium 
mobilization a likely event in the MSNs upon cotransmission of DA and other neurotransmitters 
that act at Gq-coupled receptors. 
Taken together, CODA-RET allowed investigation of functional effector coupling and 
dimer-specific pharmacology in D1R-D2R and A2AR-D2R dimers. This work uncovered a unique 
enhancement of Gi activation in D1R-D2R heterodimers. Although D1R-D2R heteromerization may 
not occur in the striatum, CODA-RET proved to be a useful assay system to specifically study 
signaling of defined dimer units as seen in A2AR-D2R study. It showed the significance of 
heterodimers in an ensemble of different signaling pathways resulting from different receptor 





does not require receptor heteromerization or Gq coupling of the dopamine receptors themselves. 
Overall, my work perhaps showed the power of dimer pharmacology as well as the danger of the 
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